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Abstract

BIOCHEMICAL CHARACTERIZATION OF SUPPRESSOR OF IKK-ε AND NAKASSOCIATED PROTEIN 1
By Jonathan L. Forbes, M.S.
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2010
Major Director: Dr. Jessica K. Bell Ph.D.
Assistant Professor, Department of Biochemistry & Molecular Biology

Innate immunity provides the first line of defense against invading pathogen by
recognizing and mounting a response to the pathogenic challenge. Among the cellular
mechanisms of the innate immune response, Toll-like receptor 3 (TLR3) recognizes viral
dsRNA and signals subsequent production of type-I interferon. The TLR3:interferon
signaling cascades contains a kinase complex composed of two kinases and a scaffold
protein, NAK-associated protein 1 (NAP1). The role of NAP1 in modulating kinase
activation or regulation is unknown. A key inhibitory protein identified in the
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xv
TLR3:interferon pathway, silencer of inhibitor of κBα kinase ε (SIKE), blocks the activity
of this kinase complex through an unknown mechanism. The long term goal of this project
is to define how protein:protein interactions modulate signal transduction in this pathway
as mediated by host in the context of an immune response, pathogen as it attempts to
subvert the host immune system and in disease states such as cancer and obesity.
Objectives for this thesis were to produce recombinant SIKE and NAP1 material that could
be used to elucidate the self-association pattern and hetero-interactions mediated by these
components within the pathway. SIKE full-length, SIKE 72 (residues 72-207), NAP 270
(residues 1-270) and NAP 255 (residues 1-255) expression constructs were completed and
recombinant protein produced using either a bacterial or baculovirus/insect cell expression
system. Self-association was characterized by size exclusion chromatography and
analytical ultracentrifugation. Hetero-interactions were explored via co-precipitation
assays of recombinant proteins. SIKE 72 formed a primarily dimeric structure whereas
NAP 255 forms a single species that appears to be monomeric at this stage of analysis.
Hetero-interactions form between the kinase TBK-1 and NAP 255 and also TBK-1 and
SIKE 72. TBK-1 shows a higher preference for binding NAP 255 in the prescence of both
NAP 255 and SIKE 72. This work provides methodology to produce recombinant material
for two components of the TLR3:interferon pathway and their initial biochemical
characterization for both self-association and hetero-interactions.

Chapter 1: Introduction

1.1 The Innate Immune System

Innate immunity provides the first line of defense against invading pathogen. All
eukaryotic organisms harbor a form of the innate immune response. This response
consists of two main components: First, defend the host by sequestering the invading
pathogen or danger signal by phagocytosis or release of small molecules to inhibit
pathogen dissemination. Second, in higher eukaryotes, activate and modulate the
adaptive immune response.
Both the innate and acquired immune systems are essential for a robust immune
response in humans [1]. Following pathogen invasion, the innate immune system reacts
within minutes to sequester the pathogen and alert the adaptive immune system, which
becomes fully activated in approximately 72 hours post infection.
The innate immune response differs from acquired immunity in three aspects; First
the response does not rely upon somatic recombination to produce an antigen-specific
antibody but relies upon recognition of evolutionarily conserved pathogen components to
activate this system. Second, the response level does not increase with redundant
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exposure, but is directly correlated to tissue type and type of infection [1]. In some body
tissues, an inflammatory response recruits more macrophages and dendritic cells.
However, in critical organs, such as the brain or heart, inflammation can be bypassed by
a macrophage response based upon phagocytosis and subsequent digestion of pathogen.
Alternatively, cells can undergo controlled cell death (apoptosis) in these tissues to
reduce inflammation [1]. Last and most importantly, the direct interaction between a
bacterial or viral pathogen via a pathogen-associated molecular pattern (PAMP) with a
host receptor mediates the innate immune response. Recognition of pathogen- or dangerderived substances over endogenous material separates a response beneficial to the host
versus an aberrant response that can lead to numerous disease state responses [1].
Macrophage and dendritic cells form the backbone of the innate response, along
with most epithelial cells located at mucosal barriers. Macrophages engulf foreign
material, digest them internally using protein degradation enzymes and lysozymes, and
release cytokines and chemokines to propagate a local inflammatory response in nearby
cells [1]. These first responders sequester foreign cells or cellular products by
phagocytosis. Dendritic cells (DCs) serve as the body’s interstitial phagocytic processor
by constantly sampling their environment. Immature dendritic cells reside in the
periphery. Upon maturation due to external/internal exposure to cytokines or bacterial
particles from phagocytosed material, they migrate to the draining lymph node, maturing
as they migrate. In the lymph node, the mature DC presents the antigenic material and
co-stimulatory molecule to naive lymphocytes, allowing for initiation of the acquired
immune response [1]. In this role, DCs function as antigen presenting cells (APCs). The
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ability to communicate an innate immune response to the adaptive immune system
represents a critical link between the two branches of the human immune system.
Upon activation, these DCs and macrophages tailor their response to the type of
infection. Similar in all responses, activated transcription factors up-regulate the
production of cytokines such as interleukin-1 (IL-1), interferon (interferon-alpha (IFN-α)
and interferon-beta (IFN-β)) and tumor necrosis factor-alpha (TNF-α) [1]. Cytokines are
generally proteins, peptides or glycoproteins that are secreted to effect the processes of
neighboring cells. Cytokines act in various ways to increase immune activity, from
initiating maturation in dendritic cells and attracting macrophages all the way to
decreasing bacterial replication and activation of the complement pathway (Table 1).
An example of a cytokine-mediated response is the release of interferon. Viral or
bacterial challenge leads to production of interferon. Interferons are so named because
they “interfere” with the replicative ability of invading pathogen [1]. Type-I interferons,
such as IFN-α and IFN-β, act as secondary messengers of a viral infection, and mediate
the activation of pathogen replication inhibitors in infected cells and also increase major
histocompatibility complex molecules (MHCI and MHCII) on uninfected cells [2]. MHC
I molecules present peptides derived from infecting pathogen for recognition by
cytotoxic or helper T cells. In addition, interferon can activate natural killer (NK) cells
and macrophages directly, with the net result being targeted toxicity of infected
cells [1].
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Table 1. Cytokines and their associated function.
CYTOKINE

TNF-alpha

IL-6

IL-8
(CXCL-8)
Type-1
Interferon

FUNCTION
Loca l Effects: Increases vascular system dilation, increases vascular permeability. Overall,
leads to increased drainage to lymph nodes.
Systemic Effects: Increased b ody temperature, systemic sho ck.
Loca l Effects: Activation of lymphocytes, increased production of antibodies by T-cells
(Acq uired Immune System).
Systemic Effects: Increased b ody temperature, production of acute phase proteins from
hepatocytes.
Loca l Effects: Recruits neutrophils, basophils and T cells to site of local infection. Allows
leukocytes to bind to site of infection by changin g the confo rmation of
integrin proteins.
Loca l Effects: Induce resistance to viral replicatio n by activating PKR to inhibit translation,
increase MHCI presentatio n, activate NK cells.
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A crucial level of response is required, however over-stimulation can have
deleterious effects on the host. For example, bacterial infection can overwhelm a host
quickly, moving beyond a localized to a systemic infection. In a systemic infection, the
innate immune response can have detrimental effects on the host. When the gram-negative
bacterial component, lipopolysaccharide (LPS), is recognized by the host, the host's innate
immune response produces the cytokine TNF- α [1]. TNF-α functions to illicit an
inflammatory response, including an increase in vascular diameter resulting in hypotension
that can starve organs of necessary nutrients. [1]. This particular hyper-response, septic
shock, results in patient death in 30-50% of the cases [2]. Death is nominally from bacterial
infection, but directly due to the hyper-activation of the innate immune response.
Evasion of the innate immune response is just as critical an issue. If a pathogen
acquires the means to either mimic or evade recognition, the step-wise dependent
dynamics between the innate and acquired immune response allows for the pathogen to
evade almost all types of immunological response. Numerous mechanisms have evolved
in viruses to circumvent immune response. In one example, viral protein (VP35) from
the Ebola virus inhibits production of interferon-β by binding to the kinases that
activate the transcription factor and acting as a competitive inhibitor for these kinases [3].
In a second example, Hepatitis C virus degrades and sequesters components of the viral
response signaling cascade [4]. Finally, influenza A decreases presentation of its PAMP
by sequestering its dsRNA [4]. These pathogens have all evolved extensive and specific
mechanisms to evade an immune response.
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In addition to hyper-active innate immune responses and evasion by pathogen, the
innate immune system can also lose its ability to distinguish between self and non-self,
targeting endogenous cells as infectious agents leading to autoimmune diseases such as
Crohn’s or Graves disease [1]. Last, but certainly not least, the innate immune response
can target non-infectious agents, creating symptoms of what are commonly referred to as
allergies. While seasonal allergies are generally a nuisance, allergic reactions to things
such as peanuts or shellfish can be fatal and are due to the body over-reacting to a noninfectious agent [5].
The human body has developed an extensive, specific and highly regulated system
in regard to finding and removing infectious agents. Multitudes of pathways and proteins
participate in these responses. The end goal of studying the immune system is to be able
to enhance the immune system's ability to recognize danger signals and to remove the
danger. Enhancing the immune response may involve increasing the innate immune
response and antibody production for vaccination, or to selectively inhibit pathogen
silencing of an immune pathway. Alternatively, induced activation of immune response
in infected tissue could help fight chronic infections or hyperplasic states. While
extensive study has been put towards this avenue of research, plenty of unknowns with
regard to mechanisms of action of the plethora of immune cascades associated with the
innate responses remain.

1.2 Pattern Recognition Receptors
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The cellular responses are based on differential recognition of endogenous and
exogenous material, with an eye towards destroying foreign infection while leaving
healthy endogenous cells intact. This delicate balance is accomplished by receptors, both
intra-cellular and extra-cellular that recognize proteins and products specific to bacterial
or viral processes. These recognized proteins and products are referred to as pathogen
associated molecular patterns (PAMP’s) [2]. These PAMP’s, of various composition and
source, are recognized by a class of protein receptors called pattern recognition receptors
(PRR) [2]. These receptors and their consequent effect on metabolic action in various cell
types allow the body to selectively respond to new or modified versions of bacterial and
viral pathogens.
The structural basis of recognition of bacterial and viral particles is mediated
PRRs. The patterns recognized by these receptors include LPS, double stranded RNA
(dsRNA), lipoteichoic acid (LTA) from gram positive bacteria and many others, all with
the common feature of being uniquely distinct from protein or molecular patterns of
endogenous cells but evolutionarily conserved in pathogens [2].
The PRRs that recognize these PAMPs are generally classified by three expansive
functions. The first class describes components that initiate phagocytosis to sequester and
eliminate pathogen by immune cells such as neutrophils and macrophages. The PRRs are
expressed on the cell surface, a good example being the mannose receptor (MR) [2].
These particular receptors recognize a distinct pattern of high mannose structures
displayed on bacteria and mediate endocytosis of the associated bacteria.
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The second category is the secreted PRRs, as they are secreted from cells to act
on the surrounding environment. These receptors have two main functions, the first being
to facilitate the complement pathway, and the opsonization of bacteria to help facilitate
targeted phagocytosis by macrophages [2]. Mainly secreted by the neutrophil
granulocytes and epithelial cells, defensins bind to microbial cell membrane, embed and
form pore-like structures that compromise the integrity of the bacterial target [7].
The last class of PRRs is the receptors that signal the presence of infection, and
they are located both extra-cellular and intracellular. Activation of signaling cascades,
such as the NF-κB pathway, generally produces responses that are pro-inflammatory [2].
The major consequence of receptor activation and subsequent signaling cascades is the
production of cytokines and transcription factors associated with both the innate and
acquired immune response. A good example of this receptor class is the Toll-like
receptor (TLR) family.

1.3 Toll-like Receptors

The Toll receptor was initially discovered in Drosophila melanogaster for its role
in embryonic development [8]. Mutations in Toll affected dorsal/ventral patterning.
Hoffman and colleagues discovered that in the adult fly, mutations in Toll compromised
the fly’s immunity to fungal infections [8]. Homologues of Toll were identified in
humans via computational homology searches and fluorescence in situ hybridization
experiments [9]. To establish a role for the human Toll-like receptors in an innate
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immune response, Janeway and Medhitov ligated an antibody to a Toll-like receptor
(TLR) and found activation of pathways capable of initiating an adaptive immune
response [10]. Beutler’s group further confirmed the innate immune function of human
TLRs by mapping a mutation known to cause endotoxin resistance (response to gram
negative bacteria) to a TLR [11]. TLRs have since been found in organisms ranging from
sea urchins to humans [2]. In humans, 10 TLRs are been identified which recognize
ligands including lipoteichoic acid, LPS, flagellin, ssRNA, dsRNA and unmethylated
CpG motifs, (Table 2).
As sentinels of microbial infection, human TLRs (hTLRs) are expressed on
immune cells such as macrophages, mast cells, dendritic cells and natural killer cells. In
addition, hTLR expression has been found in fibroblasts and keratinocytes [12,13] , NK
[14-16], and mast cells [17,18] as well as endothelial and epithelial cells [19-21]. Within a
cell, TLRs can be found at the plasma membrane (TLRs 1, 2, 4, 5, 6 and 10) to directly
sense potential pathogen in the extracellular milieu, or in an endosomal compartment
(TLRs 3, 7, 8and 9) that samples endocytosed or autophagic components [21]. The
external-membrane TLRs are activated by binding to mostly bacterially derived particles,
such as lipopolysaccharide (LPS) from gram-negative bacteria and flagellin, the
locomotive protein from flagellum-operated bacteria [22]. TLR localization, either
plasma membrane or endosomal, allows the
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Table 2. Toll-Like Receptors and their associated adaptors.
TLR

LO CAT ION

LIGAND

CO -RE CEPTO R/ ADAPT OR

1

External
Membrane

Bacterial
proteins

Hetero-dimerizes with TLR2,
MyD88

2

External
Membrane

PGN

MAL, MyD88

3

Endosome

dsRNA

TRIF

4

External
Membrane

LPS

MD-2, MAL, MyD88, TRAM,
TRIF

5

External
Membrane

Flagellin

MyD88

6

External
Membrane

Bacterial
proteins

Hetero-dimerizes with TLR2,
MyD88

7

Endosome

ssRNA

MyD88

8

Endosome

ssRNA

MyD88

9

Endosome

CpG

MyD88

10

External
Membrane

MyD88
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TLRs to be directly exposed to endogenous and exogenous protein and act as a frontline detection system for the cell. The TLRs that respond to nucleic acids are all located in
the endosome. This location is beneficial in multiple ways, the first being that this
compartmentalization allows for intracellular infection by a virus to be detected (namely
due to ssRNA and dsRNA) by normal autophagy. Alternatively, nucleic material from
damaged tissues, either infected or not, can be endocytosed and initiate an immune
response by creating distinctions between endogenous nucleic material and hallmarks of
danger [21].
Structurally, the TLRs use a similar scaffold despite the variety of ligands that are
capable of stimulating these receptors. TLRs are type I integral membrane glycoproteins
with an N-terminal ligand binding domain consisting of a disulfide bonded capping
motif, 15-24 leucine rich repeats and another disulfide bonded capping motif. The
ligand-binding domain is followed by a single trans-membrane domain, which is
connected to a C-terminal Toll/Interleukin 1 domain (TIR). This TIR domain connects
the receptor to the cytosolic signaling pathways [24]. In three-dimensional space, the
TLRs appear as a question mark in structure, with the “hoop” representing the ligand
binding domain and the “dot” serving as the cytosolic signaling domain.
Upon ligand binding to a TLR ligand binding domain, the majority of the TLRs
will either homo- or hetero-dimerize, activating a signaling cascade. TLR1 and TLR6
both hetero-dimerize with TLR2 to provide specificity for gram-positive bacterial
byproducts [23]. More recently, it has been proposed that TLR10 interacts in some way
with TLR2, however its exact ligand and activating mechanism remains unknown [23].
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Upon TLR activation, adaptor protein binds to the cytosolic TLR-TIR through a
homotypic TIR:TIR interaction. The TLRs can be divided into two classes based upon
the adaptor protein used in signaling: MyD88 (myeloid differentiation factor 88)dependent or MyD88 independent. Only TLR3 is Myd88 independent using instead the
adaptor, TIR domain containing adaptor protein inducing IFN-β(TRIF). TLR4 can
utilize both MyD88 and TRIF but requires “helper” adaptors, MyD88 adaptor-like
(MAL) and TRIF-related adaptor molecule (TRAM), respectively. Following adaptor
docking to the receptor, depending on the TLR and signaling cascade numerous adaptors
and kinase complexes are recruited with the end product being activated transcription
factors that can facilitate the cellular response.

1.4 Toll-Like Receptor 3

Toll-like Receptor 3 (TLR3) recognizes viral genomic material, namely doublestranded RNA (dsRNA), as its PAMP. The cell has multiple sensors of this unique
PAMP; TLR3, retinoic acid inducible gene-1 (RIG-I), melanoma differentiation
associated gene 5 (MDA5) and dsRNA-dependent protein kinase receptor (PKR),
however the action as well as localization of these 4 PRR’s are different (Figure 1).
TLR-3 is located in the endosome, whereas RIG-I, MDA-5 and PKR are located in the
cytoplasm [24]. Although many of the activated signaling cascades of these four
receptors are shared, unique aspects, such as eIF2α phosphorylation or involvement of
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the mitochondria, indicate a multi-faceted, independently-operated response to dsRNA
with built-in redundancy on a cellular level.
Stimulated TLR3 can activate the transcription factors nuclear factor-κB (NF-κB)
and interferon regulatory factor 3 (IRF-3). Alternatively, TLR-3 activation can lead to
cleavage of caspase 8, leading to cell death. NF-κB has been associated with the induction
of a large number of pro-inflammatory chemokines, cytokines and apoptotic proteins,
namely neutrophil adhesion proteins, TNF-α, IL-1 and COX-2 [25]. In contrast, IRF-3
phosphorylation and translocation to the nucleus is responsible, in part, for activation of
IFN-β. Upon secretion, IFN-β binds to the extracellular heterodimeric receptor interferon
alpha receptor 1/2 (IFNAR1/2), which, through the JAK/STAT pathways, activate
interferon stimulated genes. The end effect of this interferon stimulated response is to stop
protein synthesis and lead to apoptosis of virally compromised cells.
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Figure 1. Cellular sensors of double-stranded RNA.

dsRNA

Extracellular
Cytoplasm

Endosome
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PKR
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NAP1
IKK ε
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P

P

P

IKK γ

IKK β

IRF -3/7

P

P

AP-1
P
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translation

Caspase 3
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NF-κB
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P
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Pro -inflammatory
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Figure 1. Cellular sensors of double-stranded RNA. The four intracellular receptors for double-stranded
RNA and their downstream effects. RIG-1, MDA5 and PKR are distinct receptors in the cytosol, while TLR3 is located in the endosome. Activation of these receptors leads to caspase cleavage and apoptosis or
activation of transcription factor. NF-κB consists of p50 and p65, and along with IRF-3/7 serves in the
activation complex for transcription of IFN-β.
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1.5 Toll-like Receptor 3 Signaling

The activation of TLR3 leads to four distinct responses namely cleavage of
caspase 8, activation of phosphoinositide kinase-3 (PI3K) and phosphorylation and
translocation of NF-κB and IRF-3 (Figure 2)[24]. As this body of work will focus upon
the signaling cascade leading to IRF-3 activation, only this pathway will be described in
detail. Upon ligand binding, TRIF binds to the TLR3TIR domain. TRIF, in turn, binds
to its adaptor, tumor necrosis factor receptor-associated factor 3 (TRAF3), which
initiates the formation of a scaffold-kinase complex. Three scaffold proteins have been
identified that can function in the TLR3 signaling cascade, TRAF family memberassociated NF-κB activator (TANK), NAK1-associated protein 1 (NAP1), and similar to
NAP1 TBK1 adaptor (SINTBAD). Two kinases are known to associate with these
scaffold proteins, TANK binding kinase 1 (TBK-1 also known as NAK) and Inhibitor of
κB kinase epsilon (IKKε). Once activated, these kinases phosphorylate the transcription
factor IRF-3, that can then dimerize and translocate into the nucleus, leading to the
production of type I interferon (Figure 2).
Within the TLR-3/IRF-3 pathway, the function of the scaffold proteins associated
with the kinases must be addressed for their effect on pathway activation. A scaffold
protein can be loosely defined as a protein that contains a binding site for at least two
other signaling proteins. In vivo, a scaffold protein may function as a platform for
signaling molecule assembly, to localize signaling molecules, to coordinate positive or
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Figure 2. Signaling Cascades of TLR-3.
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Figure 2. Signaling Cascades of TLR-3.TLR-3 activation leads to four distinct pathways, leading to three
downstream effects. TRIF binding to the cytosolic TIR region leads to activation of Phosphoinositide-3
Kinase (PI3K), TRAF3, TRAF6 and Retinoic Inducible RIPI. A scaffold:kinase complex involving
SINTBAD, NAP1, TANK and TBK1 and IKKε leads to phosphorylation of IRF3. PI3K acts by
phosphorylating Akt. Subsequent signaling cascades leads to translocation of phosphorylated IRF3 and NFkB to the nucleus and binding to interferon stimulatory response element (ISRE), to act as part of the
transcription activation complex for production of type-1 interferon. TRIF binding to RIP1 leads to activation
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of FADD, which assembles pro-Caspase 8 activating Caspase 8 to cleave itself to the active form and
apoptotic events.
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negative feedback signals or to protect activated signaling molecules from inactivation
[26]. TANK, the most studied of the three scaffolds, is implicated in the TLR3/NF-κB
pathway but may also have links to IRF-3/7 activation [27]. Gatot et al. have shown that
TANK can be phosphorylated by TBK1/IKKε and that in response to pathway stimulation
TANK undergoes K-63 linked ubiquitinylation. What effect phosphorylation or
ubiquitinylation have on either TANK or pathway function has not yet been described.
NAP1 was first identified using a yeast 2-hybrid system with TBK1 acting as the bait [28].
NAP1 is 392 amino acids in length, and it exhibits 28% sequence similarity to TANK.
NAP1 has been shown to be the point of convergence for the TLR3 and RIG-I/mda5
pathways in the activation of IRF-3 and its knockdown could inhibit IRF-3 activation [29].
Co-immunoprecipitation experiments have shown that NAP1 and TBK1 complex, while
NAP1 does not complex with other IKK isoforms, IKKα or IKKβ [28]. How NAP1
functions to activate TBK1/IKKε is not known but Fuijita et al. suggest that NAP1 may
assist in assembly of multiple kinase units. SINTBAD, the most recently discovered
scaffold of TBK1/IKKε, also functions in the TLR3/IRF-3 pathway and may form a weak
interaction with NAP1 [30]. By comparing all three scaffold proteins, a conserved
TBK1/IKKε binding domain sequence was identified and experimentally verified [30].
Compiled together, previous work has shown that scaffold proteins contribute to the
activation of the TLR3/IRF-3 pathway, however how they may activate or modulate kinase
activity remains unknown.
In the enzymatic reactions carried out during normal cellular processes, activation
and inhibition of pathways must be coupled to allow a cell to respond to environmental
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cues but also resolve this response to basal activation levels. Loss of cellular regulation
underlies conditions such as chronic inflammation and their related diseases such as
Crohn’s disease, rheumatoid arthritics or atherosclerosis [2]. It is equally important to
understand both the positive activation and negative regulation of inflammatory
pathways.
Negative control of the TLR3/IRF-3 pathway is managed by at least three different
regulators; A20, Src homology 2 domain-containing protein tyrosine phosphatase (SHP-2)
and suppressor of IKKε (SIKE)[31]. A20 has ubiquitin ligase and de-ubiquitinylation
activity, however, this activity does not seem to be required for TLR3/IRF-3 inhibition
[24]. A20 co-immunoprecipitates with TRIF and TBK1/IKKε suggesting alternate
mechanisms are inhibiting this pathway [32]. SHP-2 is a tyrosine phosphatase associated
with positive regulation of cytokines such as EGF [33] and negative regulation of STAT1
[34]. In the TLR3/IRF-3 pathway, the C-terminal region of SHP-2 associates with the
kinase domain of TBK1 blocking IRF-3 phosphorylation [35]. Both A20 and SHP-2 are
not exclusive to the TLR3/IRF-3 pathway but can also regulate NF-κB activation. SIKE
exclusively inhibits the TLR3/IRF-3 pathway [31].
SIKE was first identified in a yeast two-hybrid system using IKKε as bait and a
human B-cell cDNA library [31]. Over expression of SIKE reduced IFN-β production
but not activation of NF-κB suggesting that this protein targets only the TLR3/IRF-3
signaling axis [31]. Using SIKE and either IKKε or TBK1 transfected cells, SIKE was
shown to co-immunoprecipitate with both IKKε and TBK-1 [31]. In a resting cell, SIKE
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associates with either kinase, but upon viral infection or dsRNA challenge SIKE is
released from the kinases. Although the exact mechanism of inhibition has not been
resolved, clearly association of SIKE with either kinase inhibits activation of IRF-3.
The TLR-3/IRF-3 pathway is one of the many viral infection response pathways
the body has. Selective activation leads to production of type-1 interferon leading to
immune response. The importance of this particular cascade is easily identifiable in that
numerous receptors can initiate its activation. The positive impact of IFN-β has been
amply demonstrated, and recent research has shown that this cytokine could be
immensely important in future cancer treatment [36]. Full understanding of the TLR3/IRF-3 pathway and how to either initiate selective activation or to abolish inhibition
could lead to more effective treatment regimens. Second, this pathway involves scaffold
proteins, the function of which are not well understood. Gaining insight into these
protein interaction networks (PINs) will help advance the field of signal transduction and
increasing the overall understanding of complex PINs utilizing similar scaffolds in other
pathways. Finally, understanding of the native inhibition of this pathway by SIKE could
lead to better understanding of how pathogens target this particular signaling event for
silencing.
This thesis was planned, executed and written with the purpose of further
elucidating how SIKE and NAP1 function in the TLR3/IRF-3 pathway to regulate and
activate this signaling cascade, respectively. First and foremost, how these two proteins
interact in a homologous state and heterologous state within the kinase complex of the
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pathway must be elucidated. Second, study how these proteins directly modulate the
kinetic parameters of TBK1 and IKKε phosphorylation of IRF-3 in vitro.

Chapter 2. Materials and Methods

2.1. Bacterial Expression Constructs and Expression

Constructs for suppressor of IKK-ε (SIKE) full length and residues 72-207 and
NAK associated protein 1 (NAP1) residues 1-270 and 1-255 in the pET15b expression
vector (Novagen) had previously been made. The pET15b vector, containing an ampicillin
selection marker, incorporates a 6X histidine tag followed by a thrombin cleavage site Nterminal to the multiple cloning site. For expression, the plasmid of interest was
transformed into BL-21 DE3 Codon + RIPL (Stratagene) competent cells following the
manufacturer’s protocol. A 50 ml Lennox Broth (LB) plus 100 µg/ml ampicillin was
inoculated with a single colony of transformed bacteria and grown overnight at 37°C, 200
rpm in an orbital shaker. Typically 2 – 1L LB/amp cultures were inoculated with 10ml of
the overnight culture and grown at 37°C, 200 rpm until A600 reached 0.6-1 absorbance
units. Cultures were then induced with 1mM isopropyl β-D-1-thiogalactopyranoside
(IPTG) final concentration and grown for 4 hours at 37°C, 200 rpm. Cells were harvested
by centrifugation, 8000 rpm for 20 minutes. Cell pellets were stored at -80°C.
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2.2.Purification and Refolding of Bacterial Constructs

Cell pellet of target protein expression was resuspended in 6 M guanidine
hydrochloride, 100 mM sodium phosphate, pH 8, 100 mM Tris-HCl, pH 8, 1 mM BME
(Buffer 1), 5 ml of buffer 1/g of cell pellet. Resuspension was stirred at room temperature
for 1 hour to solubilize all material. Homogenate was centrifuged at 12,000 rpm for 30
minutes at 4 °C. Supernatant (cell lysate) was transferred to 50 ml tubes containing NickelNTA agarose resin (10 ml - Qiagen), pre-equilibrated in Buffer 1. Samples of both pellet
and lysate fractions were prepared for later analysis by SDS-PAGE. The lysate-resin
mixture was rocked at room temperature for 90 minutes. The lysate-resin mixture was then
loaded into a 250 ml Econo-Column® (Biorad). Flow through was drained by gravity and
collected on ice. Resin was washed with 20 column volumes (CV) of Buffer 1. Buffer 1
wash was collected on ice. For refolding, a reverse gradient generator was set up with 10
CVs of Buffer 1 in the inner chamber, and 10 CVs of Buffer 2 (Buffer 1 sans guanidinium
hydrochloride) in the outer chamber. Gradient flow through was collected on ice. Resin
was washed with 2.5 CVs of Buffer 2 following the reverse gradient. Protein was eluted
off the resin with 5 CVs of Buffer 3 (Buffer 2 plus 500mM Imidazole). Elution fractions
were collected on ice. Samples of elution fractions were screened for target protein by
SDS-PAGE analysis and visualized with coomassie blue stain.

2.3 Baculovirus Expression Constructs
2.3.1 pFastbac Construct Preparation
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Constructs of SIKE and SIKE72-207 were amplified from their respective pET15b
constructs using standard polymerase chain reaction (PCR) protocol. Primers incorporated
unique restriction sites (5’SpeI or BamHI and 3’ XhoI or SpeI for SIKE and SIKE72-207,
respectively) contained in the pFASTBac vector multiple cloning site. Following
amplification, the PCR product was purified using the Qiagen PCR purification kit as per
manufacturer’s protocol. Purified PCR product and pFASTBac vector were digested with
SpeI and XhoI, or BamHI and SpeI for SIKE and SIKE72-207, respectively, for 2 hours at
37 °C. After the first hour, calf intestinal phosphatase was added to vector digest reaction.
Restriction enzyme digest products were separated on a 1% agarose gel. Bands
corresponding to target gene and vector were excised and gel extracted (Qiagen gel
extraction kit) as per manufacturer’s protocol. Vector and target gene insert were ligated in
a 1:3 ratio, respectively, using a Quick ligation kit (Roche) as per manufacturer’s protocol.
Ligated samples and controls (vector only) were transformed into α-gold competent
bacterial cells (Bioline) as per manufacturer’s protocol. SIKE pFASTBac and SIKE72-207
pFASTBac colonies were amplified in 5ml LB + 100 µg/ml ampicillin. Plasmid DNA was
isolated from the culture using a QIAprep spin mini-prep kit (Qiagen) as per
manufacturer’s protocol. DNA was eluted with sterile water. Confirmation of gene insert
was achieved using a restriction enzyme digest. Plasmids containing insert were further
confirmed by DNA sequencing.
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2.3.2 Bacmid Generation

Verified SIKE pFastbac or SIKE72-207 pFastbac DNA was transformed into
DH10Bac competent cells (Invitrogen). Briefly, DH10Bac cells were thawed on ice, 1 ng
of pFASTBac DNA was added and mixed into 100 µl of cells in a round bottom tube.
Cells were incubated on ice for 30 minutes, heat shocked at 42°C for 30 seconds, and
returned to ice for 2 minutes. S.O.C. media (900 µl) was added to cells, and cells were
incubated at 37°C, 200 rpm for 4 hours. After the incubation period, 250 µl cells were
plated onto Lennox Broth agar plates that had been pre-treated with 100 µg/ml ampicillin,
50 µg/ml kanamycin, 7 µg/ml gentamicin, 10 µg/ml tetracycline, 40 µg/ml IPTG and 100
µg/ml X-gal in DMSO. Plates were incubated at 37°C for approximately 48 hours. White
colonies were re-streaked onto Lennox Broth agar plates that had been pre-treated with 100
µg/ml ampicillin, 50 µg/ml kanamycin, 7 µg/ml gentamicin, 10 µg/ml tetracycline, 40
µg/ml IPTG and 100 µg/ml X-gal in DMSO and incubated for 24 hours. White colonies
were used to inoculate 2ml LB cultures containing 100 µg/ml ampicillin, 50 µg/ml
kanamycin, 7 µg/ml gentamicin, 10 µg/ml tetracycline.

2.3.3. Bacmid DNA Purification

Overnight cultures of pFASTBac transfected DH10Bac cells were pelleted at 9000
xg for 15 minutes at room temperature. Supernatant was removed, and pellet was
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resuspended in 300 µl of Buffer P1 (Qiagen mini-prep kit). Cells were lysed using 300 µl
of Buffer P2 (Qiagen mini-prep kit). Lysis reaction was incubated at room temperature for
5 minutes. 300 µl of 3 M potassium acetate, pH 5.5 was added drop wise with stirring,
Care was taken when mixing to avoid shearing. Solution was placed on ice for 10 minutes,
and then centrifuged at 14,000 rpm for 10 minutes at 4°C. Supernatant was transferred to
pre-chilled microcentrifuge tube containing 800 µl of isopropanol. Tubes were stored at 20°C overnight. Tubes were spun at 14,000 rpm for 15 minutes at 4°C. Supernatant was
removed. Pellet was resuspended by stirring in 1 ml of ice cold 100% ethanol. Samples
were spun at 14,000 xg for 5 minutes at room temperature. Supernatant was removed. To
the pellet, 50 µl of 1X Tris-EDTA buffer was layered on top followed by stirring. The
bacmid solution was placed on ice for 20 minutes to allow all DNA to come into solution.
Purified DNA was screened and verified by PCR. Primers used were the M13F primer (5’)
unique to the DH10Bac generated bacmid DNA, and a 3’ primer internal to the target gene.
PCR reaction and cycles were designed as per manufacturer’s protocol (Invitrogen).

2.3.4. Insect Cell Virus Propagation

All insect cell work was carried out using sterile technique in a laminar flow hood,
biosafety cabinet IIA. Sf-9 cells were cultured in Hyclone® SF-X Media (Thermo
Scientific). For bacmid transfection, Sf-9s were plated in 6-well culture plates at a density
of 9x105 cells/well. Cells were allowed to adhere at room temperature for 1 hour.
Transfection reaction was done as per manufacturer’s protocol. Briefly, in a 15 ml tube, 36
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µl room temperature Cellfectin® (Invitrogen) was added dropwise to 600 µl of media. Care
was taken not to touch sides of the tube when adding reagent. In a separate microcentrifuge
tube, 6 µg of bacmid DNA of target pFASTBac construct (SIKE FL or SIKE72-207) was
added to 600 µl of SF-X media and mixed by inversion. Cellfectin® and DNA solutions
were incubated at room temperature for 5 minutes. DNA solution was then added drop
wise to center of the Cellfectin® solution. This Cellfectin/bacmid transfection mix was
allowed to incubate at room temperature for 30 minutes. Following incubation, 4.8 ml of
SF-X media was added to the transfection solution without mixing. To each well, 1ml of
transfection solution was added drop wise to the center. Transfection solution incubated on
cells at 27°C for 5 hours. Following incubation, transfection solution was removed and
discarded, and 2 ml of SF-X media was added to each well. Cell culture plates were then
transferred to a 27°C incubator. Cell morphology was observed at 24 and 48 hours for
signs of cell lysis, indicating viral replication, compared to control, no bacmid DNA. At 72
hours, media from each plate was harvested and pooled. Fetal bovine serum (FBS) was
added to P1 viral stock to a final concentration of 3 % of volume, to protect from protease
degradation. Virus was stored at 4°C, protected from light. Amplification of a P2 viral
stock was made assuming a P1 viral titer of 1x107 pfu/ml. Sf-9 cultures in suspension
(2x106 cells/ml) were infected at a multiplicity of infection (M.O.I) of 0.1.
M.O.I (pfu/ml) (total # of cells)
Inoculum Required (ml) =

.
Viral Titer (pfu/ml)
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P2 virus was harvested when cell death was >85%, approximately 80 hours post infection.
To harvest virus, cells were spun down at 1,000 rpm. Supernatant was transferred to a new
sterile tube, 3% FBS was added and solution was sterile filtered (0.22 µm filter). P2 virus
was stored at 4°C, protected from light.

2.3.5. Determining Viral Titer

Plaquing assay to determine viral titer was completed as per Bac-to-Bac®
instruction manual (Invitrogen). Briefly, Sf-9 cells were plated at a density of 1.0 x 106
cells/well in two 6-well culture plates. Cells were adhered at room temperature for 1 hour.
Serial dilutions of P2 viral stock were made from 10-1 to 10-7 fold dilutions in SFX media.
Media was removed from cells and replaced with 1 ml of diluted virus. Each dilution of
virus was done in duplicate, along with a control (no viral addition). Wells were allowed to
incubate with virus for 4 hours at room temperature on an orbital shaker, slow speed. Low
melting temperature agarose (4 %, 10 ml) and 30 ml of SF-X media were warmed to 37°C,
and then combined to make plaquing media. After incubation, plates were returned to
hood, and plaquing media was allowed to cool but not thicken to prevent cell death. Viral
dilution media was removed from cells, and 2ml of plaquing media (cooled slightly) was
added to wells, slow addition along the wall of the well. Plaquing media was allowed to set
for 20 minutes with the lid slightly cracked to avoid condensation. Plates were placed in a
humidified incubator at 27°C for 4 days. To stain for plaques, 1 ml neutral red staining
solution, consisting of 1% agarose, 62.5 µg/ml neutral red stain in SFX media, was added
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to each well. Agarose was allowed to harden and plates were returned to humidified
incubator for 2-3 days. Plaques (cleared areas) were counted for each well, and averaged
for each dilution. Titer was calculated by:

Titer (pfu/ml) = (# of plaques) x (dilution factor) x (1ml of inoculum/well)

Viral stocks were replenished using the protocol described for P2 viral stock and titred as
described above.

2.3.6. Baculovirus Expression and Protein Purification

For small-scale trial expression, Sf-9 cells were plated in 6-well plates at a density
of 2 x 106 cells/well. Cells were infected with a viral volume calculated as follows:
M.O.I (pfu/ml) (total # of cells)
Inoculum Required (ml) =

.
Viral Titer (pfu/ml)

using an M.O.I of 3. Cells were harvested after 48 and 72 hours by washing cells from well
by repeated pipetting. Cells were pelleted at 10,000 rpm for 3 minutes. Resulting pellets
were resuspended in 500 µl of 1X PBS. To lyse, cells were sonicated on ice for 20
seconds. Resulting homogenate was centrifuged at 14,000 rpm at 4°C for 10 minutes.
Supernatant (soluble protein) was transferred to a new tube. Pellet (insoluble protein) was
resuspended in 1X PBS. Samples were analyzed by SDS-PAGE to determine solubility of
target protein expression.
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For large scale insect cell-derived protein production, 2 L of cell suspension were
infected as above. Cells were pelleted 62 hours post infection by centrifugation at 8,000
rpm for 20 minutes. Resulting pellet was resuspended in FLAG®-wash buffer (50 mM
Tris-HCl, pH 8, 250 mM NaCl, 0.5 mM NaF, 0.1% tween20, 10% glycerol, 1 tablet of
EDTA-free Complete Protease Inhibitor (Roche)) at a ratio of 15ml buffer:1g pellet. Cells
were emulsified (Avestin Emulsifex C3) as per manufacturer’s protocol (average psi
~15,000). Resulting homogenate was spun at 12,000 rpm for 30 minutes at 4°C.
Supernatant was transferred to a tube containing 15ml of FLAG® M2-agarose affinity gel
(Sigma-Aldrich) pre-equilibrated in FLAG® wash buffer, and supernatant/agarose FLAG®
was loaded onto an Econo®-column (250 ml volume, BioRad) and allowed to drain by
gravity. Resin was washed with 20 column volumes of FLAG®-wash Buffer. Target
protein was eluted with five 10 ml volumes of FLAG®-wash buffer plus 0.34 mg/ml
FLAG® peptide (Sigma-Aldrich). Resin was regenerated and stored as per manufacturer’s
protocol (Sigma-Aldrich). Samples from each step were analyzed by SDS-PAGE. Elution
fractions containing target protein were pooled and stored at 4°C. To remove FLAG®
peptide from target protein, samples were separated on a Superdex™ 200 column (GE
Healthcare) as described under the Size Exclusion Chromatography section.

2.4. Mammalian Cell Transfection Construct Preparation

Constructs of TBK-1, NAP1, TANK and SIKE 1-207 were amplified from their
respective constructs (pET15b-SIKE, pUNO-TBK1, pET15bNAP1 and pET15bTANK)
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using standard polymerase chain reaction (PCR) protocol. Primers were designed to
incorporate restriction digest sites exclusive to the pCMV-Vector multiple cloning site.
Following amplification, the PCR product was purified using the Qiagen PCR purification
kit per manufacturer’s protocol. Purified PCR product and pCMV vector incorporating
either a Myc®-tag or a HA®-tag were digested with Not1 and SalI for 2 hours at 37 °C.
After the first hour, calf intestinal phosphatase was added to vector digest reaction.
Restriction enzyme digest products were separated on a 1% agarose gel. Bands
corresponding to target gene and vector were excised and gel extracted (Qiagen gel
extraction kit) per manufacturer’s protocol. Vector and target gene insert were ligated in a
1:3 ratio, respectively, using a Quick Ligation kit (Roche) per manufacturer’s protocol.
Ligated samples and controls (vector only) were transformed into α-gold competent
bacterial cells (Bioline) as per manufacturer’s protocol. Colonies were inoculated in 5ml
LB + 100 µg/ml ampicillin. Plasmid DNA was isolated from the culture using a QIAprep
spin mini-prep kit (Qiagen) as per manufacturer’s protocol. DNA was eluted with sterile
water. Confirmation of gene insert was achieved using a restriction enzyme digest.
Plasmids containing insert were further confirmed by DNA sequencing and transformed
into α-bronze competent bacterial cells (Bioline) as per manufacturer’s protocol. A single
colony was used to inoculate 100 ml LB + 100 µg/ml ampicillin. Plasmid DNA was
purified using an EndoFree® Plasmid Maxi kit (Qiagen) per manufacturer's protocol.

2.5 Size Exclusion Chromatography
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Elutions from Ni-NTA purification and FLAG® purification were separated on a
Superdex™ 200 16/60 prep grade column (GE Healthcare) pre-equilibrated in 20 mM
HEPES, pH 7.5, 500 mM NaCl, 5% glycerol and 1 mM DTT (Buffer 4). Elution volumes
at peak maximums were converted to Kav and compared to a standard curve (Kav versus log
molecular weight) based upon globular standards of known molecular weights (previously
derived) using the equation:
Kav =

elution volume – void volume
total volume – void volume
Peak fractions for all runs were analyzed by 10% SDS-PAGE and visualized with
coomassie blue stain.

2.6 Complexing Interactions Using Size Exclusion Chromatography

TBK-1 frozen stock protein in 50 mM TRIS pH 8, 500 mM NaCl, 0.5 mM EDTA,
0.05% TritonX-100, 2mM DTT and 50% glycerol (Freezing buffer) was defrosted on ice,
and mixed in a 1:1 molar ratio with pooled NAP 270 (1 µM). Samples of TBK1 and
NAP1-270 alone were prepared at 1 µM to run as controls. All samples were incubated at
4°C overnight. Samples were loaded onto a GE Healthcare Superose™ 6 10/300 Tricorn™
column. Samples were run in Buffer 4. NAP 255 and TBK-1 were complexed as above,
except that TBK1 was a fresh preparation, not frozen. Samples were mixed in a 1:1 molar
ratio (1.8 µM). Peak fractions from all separations were analyzed by SDS-PAGE and
visualized with coomassie blue stain, followed by silver staining.
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2.7 Circular Dichroism and Thermal Melt

NAP 255 and NAP 270 target protein samples were dialyzed into 50 mM sodium
phosphate, pH 8, 50 mM sodium chloride overnight at 4°C. Dialysis buffer was retained as
a buffer blank. Aggregate was removed by centrifugation, and resulting protein solution
was diluted until A222nm ≤ 1.0. Spectra (190-300nm) were collected on a Jasco 720 Circular
Dichroism Spectrometer via collaboration with Dr. Ellis Bell at the University of
Richmond. Five individual spectra were collected, averaged and smoothed using the Jasco
Spectra Manager software. Thermal melt data were collected from 4°C-90°C at A222nm.
Data were smoothed using the Jasco Spectra Manager software.

2.8 Analytical Ultracentrifugation

Target protein samples were concentrated to an A280nm of 1.0. Sample was dialyzed
into 20 mM HEPES, pH 7.5, 250 mM sodium chloride and 5% glycerol overnight using
Spectra/Por® 7 dialysis membrane, 10,000 MWCO (Spectrum) at 4°C covered with
parafilm to prevent evaporation. Dialysis buffer was saved (50ml) in an airtight tube
immediately upon recovery. Target protein was recovered and spun down at 4,000 rpm for
7 minutes at 4°C. Supernatant was removed, and its A280nm was recorded. Sample was used
to run a sedimentation velocity experiment. Protein was loaded (410 µl) into sapphire
window cells. Data were collected using a Beckman-Coulter Optima XL-A analytical
ultracentrifuge (Beckman-Coulter) with an An-60 Ti rotor at 4°C. Runs for NAP 255 were
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collected (9.2 µM and 18.7 µM) in duplicate. Runs of SIKE 72-207 were collected (4.2
µM). Data were analyzed using SEDFIT [46] program. Solvent density and partial specific
volume were calculated using SEDNTERP program [46].

2.9 Protein Co-precipitation

Experiments were designed to utilize 10 µg of defrosted TBK-1, and 25 µg of
either NAP 255 or SIKE 72 purified and pooled from SEC in Buffer 4. Proteins alone
(controls) or mixed with potential interacting partners were incubated on ice for 1 hour
prior to dilution in cold Buffer 4 to a final volume of 1ml. FLAG®M2-agarose affinity gel,
previously equilibrated in 1X TBS and then Buffer 4 on ice, was added to each reaction
tube (20 µl of resin). A buffer control plus resin was included in each experiment.
Reactions were incubated with resin overnight at 4°C on an orbital rotator such that resin
would remain suspended. After overnight incubation, resin was spun down at 4,000 rpm
for 2 minutes at 4°C. Supernatant was removed, and resin was washed 3 times with 1ml of
ice-cold Buffer 4. Washed resin was then resuspended in 30 µl of 2X loading dye with no
reducing agent. Samples were boiled at 95°C for 3 minutes, and then placed on ice. Resin
was pelleted at 4,000 rpm for 2 minutes at 4°C , and supernatant was transferred to a new
tube. Two gels were ran, samples (15 µl) were separated by SDS-PAGE, transferred to a
nitrocellulose membrane, which was blocked in 1X Tris-buffered saline, 0.5% Tween 20
(Buffer 6) plus 5% milk and then probed with 1:1000 dilution in Buffer 6 of antibody for 1
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hour. Starting target protein (10 µg or 25 µg respectively) was also included in SDSPAGE analysis as a reference control. Two blots were probed with either anti-Flag M2
peroxidase conjugated antibody A8592 (Sigma) or α6x-His-HRP antibody (BD Clonetech)
Blots were washed 5X in Buffer 6, and and developed with standard ECL reagent (GE
Healthcare) and one-fourth Dura ECL (Pierce).

2.10 Mammalian Cell Lysate Co-Immunoprecipitations

HEK293 cells (3x105 cells/well) were seeded in 6-well plates and transfected the
following day with either Fugene® or Lipofectamine® as per manufacturer’s protocol using
4 µg of target pCMV vector. 24 hours post-transfection, cells were recovered and lysed in
0.02M Tris, pH 7.5, 0.15M NaCl, 1X protease inhibitor (Complete-EDTA free Protease
inhibitor tablet, Roche), 1X phospho-stop (Roche) and 1% NP40 (Buffer 5) by incubation
on ice for 30 minutes, vortexed for 10 seconds every 10 minutes during incubation.
Lysates were spun at 13,000 rpm for 15 minutes to pellet insoluble material. Cleared
lysates were transferred to a new tube. Lysate (800 µl) was incubated with 25 µl of antiHA antibody conjugated to agarose resin (Sigma) that was pre-equilibrated in Buffer 5
overnight on an orbital rotator at 4°C. Resin with Buffer 5 alone was included as a control.
Agarose was pelleted by centrifugation and washed 3X with 1 ml Buffer 5, and layered
with 40 µl of Buffer 5. Agarose was resuspended in 60 µl 2X loading dye and boiled for 3
minutes at 95 °C. Samples were spun down and supernatant was transferred to a fresh tube.
Samples were separated by SDS-PAGE, transferred to a nitrocellulose membrane, which
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was blocked in 1X Tris-buffered saline and 0.5% Tween 20 (Buffer 6) plus 5% milk and
then probed with 1:1000 dilution in Buffer 6 of antibody for 1 hour. Antibody used was
anti-HA.11 antibody (Covance) for 1 h in Buffer 6. Blot was washed 3X with Buffer 6 and
probed with 1:5,000 secondary antibody, goat anti-mouse IgG conjugated to horseradish
peroxidase (HRP), in Buffer 6 for 1 hour. Blot was washed 3X with Buffer 6 and
developed with standard ECL reagent (GE Healthcare) and one-fourth Dura ECL (Pierce).
For further study, HEK293 cells were plated as previous, however 24 hours posttransfection with Lipofectamine with 4 µg pCMV-HA-SIKE FL cells were incubated for
24 hours or stimulated with 50 µg of pI:pC for 24 hours. Lysates were recovered and
immunoprecipitated with anti-HA resin as previously described, and samples were
separated by SDS-PAGE and transferred to nitrocellulose membrane. For phosphoserine
screening, SDS-PAGE gel was transferred to PVDF membrane (Bio-rad), blocked in
Buffer 6 with 5% BSA for 1 hour and washed 3X with Buffer 6. Antibody antiphosphoserine 05-1000 (Upstate) was diluted 1:1000 in Buffer 6 with 5% BSA and probed
for 1 hour. Blot was washed for 20 minutes 3X with Buffer 6 and probed with 1:5,000
secondary antibody, goat anti-mouse IgG conjugated to horseradish peroxidase (HRP), in
Buffer 6 for 1 h. Blot was developed as previously described. For ubiquitin screening,
protocol was the same as the anti-HA probe with exception of primary antibody used was
anti-Ub (sc130410 Santa Cruz).
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2.11 Crystallization Trials

SIKE 72-207 was concentrated to 6.98 mg/ml in Buffer 4. A factorial screen,
Qiagen Classics Suite, was setup in a Corning® Protein Crystallography non-treated 3:1 96well plate using 1 µl protein solution and 1 µl well solution. Plate was incubated at 18 °C
and results were interpreted 2 weeks and 4 months after setup. Wells were scored as clear,
precipitate, microcrystalline or crystal. A second screen was set up for SIKE 72-207 at
4.98 mg/ml using the PEGs Suite (Qiagen). Results were scored 2 weeks and 4 months
after set up.

2.12 Protein Concentration

Protein concentrations were determined by BioRad protein assay (BioRad) as per
manufacturer’s protocol. As needed, protein samples were concentrated by ultrafiltration
technique (Centriprep or Amicon Ultrafiltration Units, Millipore Corp.).

Chapter 3. Results

Review of the predicted domain structure of the scaffolds, kinases and SIKE
immediately suggests the potential importance of coiled-coil mediated interactions (Figure
3). All six proteins involved at this particular step in the cascade are predicted to have at
least one coiled-coil domain. These elements can form important interactions at points of
homologous and heterologous protein binding and are capable of forming dimeric up to
heptameric interactions [6]. In this thesis, how the coiled coil domain of these kinase
complex components participate in protein:protein interactions has begun to be defined.
3.1 Expression of Constructs

The first step in elucidating a mechanism of activation/inhibition or protein
interactions in vitro involves production of soluble, pure and stable protein constructs.
Protocols to produce recombinant kinases from insect cell culture had previously been
developed and implemented (R. J. Call personal communication). Initial experiments to
produce full-length (FL) SIKE in bacteria resulted in insoluble material using several
bacteria cell lines and induction temperatures (R. J. Call personal communication, Figure
4).
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Figure 3. The Kinases, Scaffolds and Inhibitor of the TLR-3 IKKε/TBK1 Pathway

Figure 3. The Kinases, Scaffolds and Inhibitor of the TLR-3 IKK-e/TBK-1 Pathway
This figure diagrams the predicted domain structure of the players involved TLR-3:IKK-e/TBK-1 Pathway.
Overview of the structures suggests the importance of the coiled-coil interactions for this particular pathway;
predicted coiled-coil domains are depicted in black. Preliminary review of sequences has allowed for a loose
prediction of Scaffold Binding Motif for the kinases, which is on the c-terminal portion and is hatched in
color. The scaffolds also have their predicted Kinase Binding Domain (KBD) depicted in hatched coloring,
and the inhibitor SIKE also has a predicted KBD depicted in hatched coloring. SINTBAD is another
identified scaffold that was not currently under study based on its complexity.
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Figure 4. Solubility of SIKE Full Length

Figure 4. Solubility of SIKE Full Length. SIKE FL pet15b plasmid was transformed into DE3 RIPL
bacterial competent cells. Cells were grown at 37 °C until A 600 = 1.0. Cultures were induced with either 0.1
mM or 1 mM IPTG. Cultures were then incubated at either 37 °C or 16 °C for 4 hours or overnight
respectively. Cultures were pelleted and resuspend in 1X PBS and sonicated for 30 seconds, 3 times. Small
sample of homogenate was saved (Whole Cell Lysate), the rest was centrifuged, and supernatant was
transferred to a new tube representing the soluble fraction. Pellet was resuspended in water and represented
the insoluble fraction. Samples were separated by SDS-PAGE. SIKE FL is insoluble.
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Insoluble material was purified under denaturing conditions on an immobilized
metal affinity chromatography column (IMAC) and refolded using a linear reverse
gradient. Purified SIKE was analyzed by size exclusion chromatography to assess native
molecular weight and oligomeric state. Separation by SEC revealed multiple species,
indicating that SIKE could form multiple oligomeric states. Although known to form
oligomers [31], SIKE’s native state could not be ascertained from this experiment nor
could this heterogeneous material be used to further study protein:protein interactions.
Only amino acids 72-207 of SIKE (SIKE 72) are necessary to immunoprecipitate
TBK-1 and IKK-ε [31]. This shortened version, previously inserted into a pET15b
expression vector, was transformed into BL21de3 cells. Again, the initial trial yielded a
protein that was insoluble. Lowering induction temperature, to enhance folding, had no
effect on solubility (Figure 5). BL21de3 Codon+ cells, which contain tRNA synthetases
for E. coli rare codons and would enhance expression of human-derived sequences like
SIKE, again, had no effect on solubility.
Based upon these difficulties with bacterial production of SIKE, an insect cell
expression system was attempted for both SIKE 72 and SIKE Full Length (SIKE FL).
Insect cells are more advanced on an evolutionary standpoint compared to bacterial
expression systems; Insect cells have more chaperones to assist in the protein folding
processes. This feature would favor producing a stable and soluble SIKE construct. To
utilize insect cells for expression, the gene of a target protein must be delivered to the
insect cell via a baculovirus. To produce recombinant baculovirus containing the target
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Figure 5. Solubility of SIKE 72.

Figure 5. Solubility of SIKE 72. SIKE 72-pET15b plasmid was transformed into de3 RIPL bacterial
competent cells. Cells were grown at 37 °C until A600 = 1.0. Cultures were induced with either 0.1 mM or 1
mM IPTG. Cultures were then incubated at either 37 °C or 20 °C for 4 hours or overnight respectively.
Cultures were pelleted and resuspend in 1X PBS and sonicated for 30 seconds, 3 times. Homogenate was
centrifuged, and supernatant was transferred to a new tube representing the soluble fraction. Pellet was
resuspended in water and represented the insoluble fraction. Samples were separated by SDS-PAGE. SIKE
72 is insoluble.
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gene required introduction of target gene into the viral genome. . First, the gene was
inserted into the pFASTBac vector, a phage shuttle vector. SIKE (FL or 72) pFASTBac
was then transformed into DH10Bac competent cells, which carry the baculovirus genetic
material (bacmid DNA). Through a homologous crossover event, the target gene is
incorporated into the bacmid DNA. The homologous crossover has a low efficiency for
producing SIKE containing-bacmid DNA. To screen for positive crossovers, colonies
were selected based upon antibiotic resistance and galactosidase activity, as successful
recombination should disrupt galactosidase gene product but retain antibiotic resistance.
Complicating selection, colonies were mostly white upon initial growth, but often when restreaked under the same selection would reveal galactosidase activity. Positive colonies
were amplified in suspension and their DNA was isolated. Bacmid DNA isolation had
numerous issues. Sensitivity to DNA shearing due to its larger size, was avoided by not
pipetting to resuspend but rather using the pipette tip to gently stir solution. Even after
resuspension, DNA could be compromised. Initial attempts using a Bacmid DNA Isolation
kit from Invitrogen resulted in DNA pellets that were insoluble. This insolubility was
coincident with allowing pellets, following ethanol precipitation and washing, to air-dry
too long. Repeated attempts decreasing dry time from 10 minutes to almost 1 minute did
not result in a soluble pellet. Changing the resuspension solution to either sterile water or
Tris-EDTA, pH 8 buffer failed to have any effect on insoluble pellets. Pellets were also
warmed in a 37°C degree water bath for 10-60 minutes but pellets remained insoluble. The
final protocol that allowed for resuspension of the bacmid DNA pellet included an
increased incubation on ice following resuspension in iso-propanol, and upon pelleting to
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use 1ml of ice-cold ethanol and resuspend by “blasting” the pellet immediately. After
spinning and pulling off ethanol, the pellet was allowed to air dry on an incline on a towel
for 5 minutes. The pellet was then layered with ice cold TE Buffer and incubated on ice for
20 minutes with occasional mixing. Resuspension was incubated at 4 °C and took
approximately 24 hours. The resulting bacmid DNA was screened using a standard PCR
protocol with a bacmid-based 5’ primer (M13Forward) and a 3’ primer internal to the
target gene (Figure 6). Amplification indicated insertion as well as correct orientation.
Using this protocol, human Toll-like receptor 3 full-length pFASTBac and bacmid DNA
were also produced, however this construct was not used in any of my further studies (data
not shown).

Virus was prepared as noted in the methods. Subsequent amplification and titer
quantification were completed for both SIKE FL and SIKE 72. Both viruses were
amplified to a volume of 200 ml each before being titred, and the subsequent titers were as
follows:

SIKE FL -

1.48 x 107 pfu/ml

SIKE 72-207 –

1.73 x 107 pfu/ml

hTLR-3 -

3.60 x 107 pfu/ml

Following viral quantification, insect cells were infected with target baculovirus in 6-well
plates. Single infections of both SIKE FL and SIKE 72-207 viruses were carried out as
described in the methods section. Resulting cell pellets were resuspended in 1X
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Figure 6. SIKE FL and SIKE 72 Bacmid Generation.

Figure 6. SIKE FL and SIKE 72 Bacmid Generation. The initial step of the bacmid construction was
insertion of SIKE FL or SIKE 72 into a pFastbac vector. A.) SIKE FL restriction digest of vector shows
pFastbac vector and SIKE FL DNA (arrow) B.) Restriction digest of vector shows pFastbac vector and SIKE
72 DNA (arrow). Due to the low concentration of vector, gel was overexposed making a marker hard to
identify, however an underexposed picture was taken as well (data not shown). C.) PCR screen using purified
SIKE FL Bacmid DNA as templates (3 in total), using an M13F primer specific for the Bacmid vector and an
internal primer that sets down around residue 163 in the SIKE construct. Amplification indicates insertion as
well as orientation. Only 1 of 3 samples screened was positive. D.) PCR screen using purified SIKE 72
Bacmid DNA as templates (3 in total), using an M13F primer and the 3’ SIKE FL/72 primer used for initial
amplification. Again, amplification indicates insertion as well as orientation. All 3 samples were positive.
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PBS, and sonicated for 30 seconds on ice. Soluble and insoluble fractions were separated
by centrifugation, prepared for SDS-PAGE analysis and separated on a 10% SDS-PAGE
gel. SIKE FL and SIKE 72 are insoluble in single infections (Figure 7). Co-infections of
SIKE FL + TBK1 virus or SIKE FL + IKKε were completed. R. J. Call provided virus for
TBK1 and IKKε. Based upon the idea that SIKE bound to the kinases [31] and that kinases
were produced as soluble proteins from insect cell culture, co-expression of SIKE + kinase
would either stabilize or pull SIKE into the soluble fraction. In addition, if these proteins
formed a stable complex, SIKE could be purified utilizing the kinase purification scheme.
SIKE FL and SIKE 72 double infection experiments were completed, and results for both
constructs were the same (Figure 8). Both experiments were consistent with insoluble
SIKE upon double infection . A small percentage of total SIKE expression may separate to
the soluble fraction. However, a Western blot, run to confirm localization to the insoluble
fraction, revealed that this construct did not contain an engineered FLAG®-tag. The
incorrect pFastBac plasmid was used in the initial construct formation. However, these
experiments show conclusively that SIKE FL and SIKE 72 are mostly insoluble. No
further work was completed using the insoluble SIKE material from insect cells as bacteria
could provide the same starting material more economically. Characterization of SIKE was
exclusively on bacterially produced and refolded SIKE 72 (Figure 9).
The scaffold protein, NAP1, was produced exclusively in bacteria. Full length
NAP1 expressed as insoluble material. Two constructs, NAP 1-270 and NAP 1-255,
containing the coiled coil region and kinase interaction site, had previously been prepared.
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Figure 7. Solubility of Bacmid-derived SIKE FL
A.

B.
Figure 7. Solubility of Bacmid-derived SIKE FL. Sf-9 cells in 6 well plates were infected with
SIKE FL Baculovirus. Control plates had no viral infection. Cells were incubated at 27 °C and harvested at
either 48 or 72 hours. Upon harvesting, cells were pelleted and resuspended in 1X PBS. Cells were sonicated
and centrifuged. Supernatant was the soluble fraction, and pellet resuspended in water was the insoluble
fraction. The time points and soluble and insoluble fractions (S,I) are shown. SIKE FL, upon infection, is
insoluble. Repeated experiment on SIKE 72 Baculovirus was consistent with this result (data not shown).
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Figure 8. Double Infections of Bacmid TBK1, IKKε and SIKE FL.

Figure 8. Double Infections of Bacmid TBK1, IKKε and SIKE FL. Sf-9 cells in 6 well plates were
infected with SIKE FL Baculovirus along with either TBK1 or IKKε Baculovirus. Control plates had no viral
infection. Cells were incubated at 27 °C and harvested at either 48 or 72 hours. Upon harvesting, cells were
pelleted and resuspended in 1X PBS. Cells were sonicated and centrifuged. Supernatant was the soluble
fraction, and pellet resuspended in water was the insoluble fraction. Infections (TBK1+SIKE (S/T), IKKε
+SIKE (S/I) and TBK-1+IKKε (T/I)), their time points and soluble and insoluble fractions (S, I) are shown.
SIKE FL, upon double infection, is insoluble, and SIKE 72 Baculovirus was consistent with this result (data
not shown). While there might be a small portion of SIKE in the soluble portion, majority of SIKE is
insoluble.
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Figure 9. Refolding of SIKE 72-207 From BL-21 Codon+ Expression.

Figure 9. Refolding of SIKE 72-207 From BL-21 Codon+ Expression. Two liters of SIKE 72-207 culture
were lysed in 6M Gud-HCL and membrane and organelles were removed by centrifugation and a sample of
this pellet was saved (pellet). The lysate from this step was loaded onto a Ni-NTA column and allowed to
drain by gravity flow (lysate) and then washed with 100 ml of Gud-HCl buffer (Unbound). Column was then
subjected to a reverse gradient to remove all guanidine (Reverse Gradient). Protein was eluted using 5
volumes of 5ml of elution buffer (0.5M Imidazole). The resulting elutions are numbered e1 to e4.
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Figure 10. Refolding of NAP 1-270, NAP 1-255 From BL-21 Codon+ Expression

A.)

B.)

Figure 10. Refolding of NAP 1-270, NAP 1-255 From BL-21 Codon+ Expression. A.) Two Liters of NAP
1-270 culture was lysed in 6M Gud-HCL and membrane and organelles were removed by centrifugation and
a sample of this pellet was saved (pellet). The lysate from this step was loaded onto a Ni-NTA column and
allowed to drain by gravity flow (lysate) and then washed with 100ml of Gu-HCl buffer (Unbound). Column
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was then subjected to a reverse gradient to remove all guanidine (Reverse Gradient). Protein was eluted using
5 volumes of 5ml of elution buffer (0.5M Imidazole). The resulting elutions are numbered e1 to e4.
* denotes a conserved degradation product. NAP 1-270 is a construct with an isotopic molecular weight of
approximately 33.5 kDa.
B.) NAP 1-255 was refolded in the same protocol and samples are labeled the same as A. NAP 1-255 had a
small degradation portion as well, however it was not pulled through during SEC. NAP 1-255 has an
isotopically averaged molecular weight of 29.7 kDa.
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When expressed in BL21de3 Codon+ bacteria both constructs separated to the insoluble
fraction. These proteins were refolded as described in the methods section. Elution
fractions from the IMAC column were prepared for SDS-PAGE analysis and separated on
a 10% SDS-PAGE (Figure 10). In all preps of NAP 1-270, a significant band at
approximately 10 kDa was observed. These recombinant forms of NAP 1-270 and NAP 1255 were biochemically characterized.

3.2 Characterization of Constructs
3.2.1 Size Exclusion Chromatography (SEC)

Purified, refolded target proteins were subjected to size exclusion chromatography
(SEC) separation, which provided information about the oligomeric structure and
molecular size of the constructs. In an SEC experiment, macromolecules in solution
tumble as spherical species and are separated based upon their ability to interact with resins
containing different size pores. Species too large to interact with the resin elute first
whereas species that interact with resin/pore elute later allowing for a size distribution of
species to be determined. Molecular weights of species can be derived by comparison to a
standard curve of globular proteins with well-defined molecular weights. In the set of
proteins under study here, the coiled coil domains found in each construct forms a nonglobular, helical rod. When tumbling in solution, these coiled coil domains give an
apparent hydrodynamic radius that correlates with a much larger species than the actual
construct. While SEC can give information on purity and stability of target proteins, the
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actual size determination can only be loosely applied. For example, in previous research,
SEC of the NAP 1-200 coiled-coil domain produced peaks that corresponded to a hexamer
and a 12-mer, but when analyzed by another technique were found to be monomer and
dimer species (R. J. Call personal communication). The SEC chromatographs for SIKE FL
(26kDa) and SIKE 72 (17.5 kDa) are shown in Figure 11. SIKE 72 formed a stable, single
species, and was used for all subsequent analysis. Size correlation showed the nonaggregate peak corresponded to 66 kDa (a tetramer). Separation of peak fractions by SDSPAGE shows that the single peak contained a single band corresponding to SIKE 72
(Figure 11b). SIKE 72 fractions were pooled and used for further analysis.
Approximately 2-3 weeks after pooling, SIKE 72 would aggregate and precipitate out of
solution.

NAP 1-270 (35 kDa) and NAP 1-255 (32 kDa) SEC show that each construct
contained non-aggregate but multiple species (Figure 12, Figure 13). A sloping shoulder
on the lagging edge of the major peak in both constructs suggests multiple species are
present. SDS-PAGE analysis of the fractions from the NAP 1-270 SEC showed that the
lagging edge had a contaminant protein at ~10 kDa (Figure 12b). This band was shown by
western blot to incorporate a 6X His-tag (Figure 12b), indicating that this protein is a Cterminal truncation of the full NAP 1-270 construct and was likely responsible for the
lagging shoulder peak in the SEC chromatograph. Interestingly, the smaller, clipped
fragment of NAP1-270 that retains portions of the N-terminal coiled-coil domain
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Figure 11. SEC of SIKE 72-207.

Figure 11. Size Exclusion Chromatography of SIKE 72-207. Elutions from the refold were loaded in 5ml
quantities onto a s200 column and run in Buffer 4. All 5 fractions had the same profile, with various
differences between concentration of aggregate and the single species. Size correlation of the main species
fcorrelates to approximately 66 kDa based on globular standards. The resulting SDS-PAGE analysis of the
elution fractions is represented in B, and you can see that the protein is pure. This indicates that the
differences in elution volume are based on self-associations not contaminant products.
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Figure 12. SEC of NAP 1-270 and SDS-PAGE Analysis of Elution Fractions

Figure 12. SEC of NAP 1-270 and SDS-PAGE Analysis of Elution Fractions A. Elutions from the refold
were loaded in 5ml quantities onto a Superdex™ 200 16/60 prep grade column (GE Healthcare) and run in
Buffer 4. All 5 fractions had the same profile, with various differences between concentrations of the main
peak. As you can see, there is an extreme shoulder on the lagging edge of what is the main species. This
indicates that there is more than species present. B. Resulting analysis of every other elution fraction
confirms the SEC characterization. From the leading edge to the back end of the peak, an increase in smaller
species at ~25kDa and ~10kDa (denoted with asterisks) is seen. C. Western blot of protein from fraction 88
with a 6X His antibody. This shows that the lower band incorporates a His-tag, indicating that this is a C-
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terminal truncation of the full construct. With this knowledge in hand, only the leading 8 fractions were
pooled for further study.
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Figure 13. SEC of NAP 1-255 and SDS-PAGE Analysis

Figure 13. SEC of NAP 1-255 and SDS-PAGE Analysis of Elution Fractions A. Elutions from the refold
were loaded in 5ml quantities onto a Superdex™ 200 16/60 prep grade column (GE Healthcare) and run in
Buffer 4. All 5 fractions had the same profile, with various differences between concentrations of the main
peak. An extreme shoulder on the lagging edge of what is the main species is observed. This indicates that
there is more than species present. B. Resulting analysis of every other elution fraction confirms the SEC
characterization. There were no smaller species of the NAP255.
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retains a His-tag, indicating is it a C-terminal trunction of our full length construct.
Fractions from NAP 1-255 showed a clean sample, with a single band at ~32 kDa (Figure
13). Based on the domain structure of NAP 1-255, the elongated peak may represent
protein in a self-associated species, while the lagging edge represents protein in monomer
state. For further analysis, the leading edges of SEC peaks (corresponding to the first 8
fractions of the peak and never extending past the mid-line of the first major peak) for both
constructs were pooled and concentrated.

TBK-1 (83 kDa) purification was carried out as described in the Methods section.
The SEC chromatograph of the purified kinase and SDS-PAGE analysis of peak fractions
is shown in Figure 14. The single species correlates to a molecular weight of ~ 130 kDa
(1.5-mer). This could correspond to either a monomer-dimer equilibrium or an nonglobular monomer.

3.2.2 Complexing Interactions

One of the driving points of my research was to establish the criterion that is
necessary for the formation of a complex between NAP constructs and full length TBK-1.
To further pursue the structural importance, it would be necessary to confirm in vitro if the
kinase binding domain (KBD) of NAP1, previously identified by immunoprecipitation
assays, directly mediated this interaction [30]. This would allow for further study utilizing
sequence mutations to identify the critical interaction points. Previous research had
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Figure 14. SEC of TBK-1 and SDS-PAGE Analysis
A.)

B.)

Figure 14. SEC of TBK-1 and SDS-PAGE Analysis. A. Bacmid derived TBK-1 elution fractions were
separated in Buffer 4 on a Superdex™ 200 16/60 prep grade column (GE Healthcare). All 5 fractions had the
same profile, with various differences between concentrations of the two peaks. B. Resulting analysis of
every other elution fraction from the second elution peak confirms the SEC characterization. TBK-1 was
pure and stable.
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established that sequences between residues 198-270 were necessary to immunoprecipitate
TBK-1 in vivo and a potential kinase binding domain sequence identified at residues 216255 [30]. While the immunoprecipitation data indicates that TBK-1 and NAP1 associate, it
fails to show a direct interaction between the two or if post-translational modifications
might be required for binding. With regard to the latter, the NAP1-KBD is rich in serines,
which could be phosphorylated and alter binding to TBK-1. To initiate this line of
experiments, TBK-1 was complexed with both NAP 1-270 and NAP 1-255 and SIKE 72.

NAP 1-270 was complexed with recombinant TBK-1 that had been previously
purified and stored at –80°C. Each protein was incubated both alone and in protein
complex in gel filtration buffer (Buffer 4) in a 1:1 molar ratio overnight at 4°C. These
incubation reactions were separated consecutively on Superose™6 Tricorn™ column in
buffer 4. Chromatographs for each run are shown in Figure 15. Comparison of TBK1 SEC
separation during purification versus the TBK1 used in this complexing reaction show
additional peaks in the TBK1 sample that had been frozen. These results indicate that
TBK1 should be used immediately after purification or conditions for freezing need to be
optimized to retain stable TBK1 structure. Also, based upon the clipping observed during
purification of NAP 270 and the additional species present in the SEC separation due to
this fragment, the NAP 1-255 construct would be better suited for protein
interaction studies with TBK1. No SDS-PAGE analysis was completed on peak fractions
due apparent degradation of TBK1 component.
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Figure 15. SEC of Complex of NAP 270 with TBK1.

Figure 15. SEC of Complex of NAP 270 with TBK1. Pooled NAP 270 from SEC of the refold was allowed
to complex with purified TBK-1 that had been frozen down by Jason Call. Samples were set up as per
methods, and loaded onto a Superose 6 Tricorn SEC Column. The resulting chromatograms are depicted.
TBK-1 ran in an altered state, indicating that the freezing protocol and process had adverse effects on
stability and state of the protein. Based on this, no SDS-PAGE analysis was completed due to the fact that
TBK-1 might not have retained a native fold so any conclusions that could be drawn would not be ideal.
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NAP 255 was purified, pooled, and complexed with freshly prepared TBK-1. Both
proteins were concentrated (NAP255: 0.155 mg/ml TBK1: 0.113 mg/ml) and mixed in a
1:1 molar ratio or incubated alone at the same concentration. Samples were incubated
overnight at 4°C and separated on the Superose™ 6 Tricorn™ SEC column. The resulting
chromatograms are overlaid in Figure 16. Peak fractions from each separation were
analyzed by SDS-PAGE, Figure 16 b-d. Neither the chromatograms nor SDS-PAGE
analysis conclusively state that a TBK1:NAP 1-255 complex has formed. While no peaks
shift location, also no split peak indicating two distinct species is seen. Complicating the
interpretation, TBK-1 and NAP 1-255 elute at almost the same volume. Based on band
intensity from the SDS-PAGE, NAP 255 is more concentrated towards the leading edge of
the peak and TBK-1 is more concentrated towards the middle fractions of the peak. This
indicates that these particular proteins may not interact but co-elute. While TBK-1 runs as
large monomer, addition of a single NAP monomer would only shift peak location by
approximately 0.25ml based upon this column’s separation parameters.

In addition to complex formation assessed by SEC, a simple co-precipitation
experiment was completed. Recombinant TBK-1 from insect cells contained an N-terminal
FLAG®-tag. The NAP 1-255 construct contained an N-terminal 6X His-tag. For this in
vitro co-precipitation experiment, two proteins containing different tags were incubated
together. Resin capable of binding one of the two proteins was added to the incubation and
allowed to bind its target protein. Resin was pelleted to remove from solution the target
protein directly associated with the resin but also any protein capable
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Figure 16. Complex of NAP 255 with TBK1

Figure 16. Complex of NAP 255 with TBK1 A. SEC Chromatograms of NAP 255 alone, TBK-1 alone and
incubated NAP 255 – TBK-1 complex. Samples were run in a total volume of 500ul in a 1:1 molar ratio on
the Superose6 TricornAgarose column. This column was chosen for the potential increase in size of a
complex formation. No discernible shift in peak location from complex is observed, however this could be
due to the ratio of TBK-1 to NAP with regards to homologous interactions. B. SDS-PAGE analysis of TBK-1
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alone, and the bands are located at approximately 83 kDa. C. SDS-PAGE analysis of the six elution fractions
from NAP 255 correlating to the peak and lagging fractions. Majority of sample was located in the main
peak, as you can see from the band at 31 kDa in the third fraction. D. SDS-PAGE analysis of each fraction
under the peak for the complexing interaction. A higher concentration of NAP 255 on the leading edge, and a
gradual increase and decrease of TBK-1 as you progress across the peak Is observed. Based on the location
of the concentrations of the two constructs and the fact that there is no mutual overlap of concentrations, it is
possible that complexing did not occur.

65
of binding the target protein. Resin was washed to remove loosely bound or nonspecifically bound proteins. Bound proteins were released by addition of SDS and boiling.
Samples, including starting material, were analyzed by SDS-PAGE. Control included
individual proteins incubated with resin and resin alone. The protocol was carried out as
described in methods. Initial experiments using FLAG® resin to precipitate TBK1 failed to
directly pull down NAP 1-255. This result was found to be due to NAP 1-255 degradation
by the time of its use. A new prep of NAP 1-255 was completed; however by this point
TBK1 had degraded to a sufficient point that, again, the experiment was not conclusive.
Preps for both TBK1 and NAP 1-255 were re-done with an eye towards having freshly
purified protein of each construct at the same time. Inclusion of the starting material lanes
also allowed direct analysis of the exact concentration used for the co-precipitation.
Incidentally, a fresh preparation of SIKE 72 was also completed at this time. Proteins were
complexed and co-precipitated as per methods. The SDS-PAGE and subsequent western
blot utilizing α-Flag and α-His antibodies is shown in Figure 17. TBK-1 pulled down both
the SIKE 72 and the NAP 255 construct, however upon addition of both, TBK-1 seems to
have a higher affinity towards NAP255, indicating that without any post-translational
modifications NAP might have a higher affinity for TBK-1.

3.2.3 Circular Dichroism and Thermal Melt

When a refolding protocol is used to obtain recombinant material, one must
confirm that a native, folded state has been reached. For proteins having enzymatic

66
Figure 17. Co-precipitation of NAP 255 and SIKE 72 with TBK1.

A.

Figure 17. Co-Precipitation of NAP 255 and SIKE 72 with TBK1. A. 20 µg of 6X-His-tag NAP255 or
6X-His-tag SIKE72 alone or in combination were allowed to complex for 1 hour on ice with 10 µg Flag®tag TBK-1 in buffer 4. Samples were then diluted to 1 ml in buffer 4. Controls of each protein alone, along
with buffer were incubated with anti-Flag® M2 affinity agarose gel (20 µl) overnight on a circular rotator.
After washing and boiling, samples were separated by SDS-PAGE and transferred to nitrocellulose
membrane for immunoblotting with α-Flag or a α-6X-His antibody. Resulting western blots are depicted. A.)
Starting material was homogenous for all samples with the exception of a small cleavage of NAP255. TBK-1
was pulled down in all reactions it was added too, indicating that the affinity tag was intact. α-Flag resin had
no affinity for either NAP255 or SIKE72 alone. Subsequent addition of SIKE 72 and NAP255 constructs
with TBK-1 allowed them to co-precipitate. Upon addition of all three proteins, NAP255 co-precipitated with
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TBK-1 however SIKE 72 was now absent. While densitometry was not completed, the NAP255 that was
pulled down in the presence of TBK-1 and SIKE 72 is less concentrated.

68
activity, a simple assay confirms a native fold. In the absence of a functional assay,
presence of stable secondary structure can be used as an indicator of a folded protein.
Neither SIKE nor NAP1 constructs can be functionally assayed so circular di-chroism
(CD) spectra were collected on these constructs to confirm secondary structure content and
stability. CD
spectra and thermal melt of the constructs NAP 270 (Figure 18) and NAP 255 (Figure 19)
show that both have alpha-helical character as expected for their coiled coil domains.
However, their thermal melt profiles show significant differences in their secondary
structure stability. NAP 270 has very little stepwise loss of helical content occurring as
temperature increases. A straight line is included for comparison. This indicates while
alpha-helical character in the coiled coil domain is intact the overall tertiary interactions
are weak or absent. Looking at the NAP 255 thermal melt, stepwise loss of alpha helical
content to unfolded state can be followed indicating a potential non-monomer association
and a stable tertiary structure. The thermal melt data suggests that the NAP 255 construct
contains tertiary/quaternary structure.

3.2.4 Analytical Ultracentrifugation
Final determination of the oligomeric state of the constructs was completed using
analytical ultracentrifugation (AUC) sedimentation velocity (SV) experiments. Numerous
complications were overcome to collect data. First and foremost, the constructs had limited
solubility. Buffers ideal for AUC, without stabilizing agents such as high salt, glycerol or a
reducing agent (DTT or BME), greatly diminished target protein solubility. Use of glycerol
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Figure 18. Circular Dichroism and Thermal Melt of NAP 270.
A.)

B.)

Figure 18. Circular Dichroism and Thermal Melt of NAP 270. Samples of NAP270 from SEC
experiments were dialyzed into 0.05 M Phosphate pH8 and 0.05 M NaCl. Dialysis buffer was kept as a
blank. Samples were scanned 5 times, and the results were averaged by Jasco CD Software. Sample was then
subjected to a thermal melt from 4 °C to 85 °C measuring ellipticity at A222. CD spectra indicate an alphahelical structure, while the thermal melt shows negligible stepwise function for unfolding.
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Figure 19. Circular Dichroism and Thermal Melt of NAP 255.
A.)

Ellipticity

Wavelength, nm

B.)

Figure 19. Circular Dichroism and Thermal Melt of NAP 255. Samples of NAP 255 from SEC
experiments were dialyzed into 0.05 M Phosphate pH8 and 0.05 M NaCl. Dialysis buffer was kept as a
blank. Samples were scanned 5 times, and the results were averaged by Jasco CD Software. Sample was
then subjected to a thermal melt from 4°C to 95°C measuring ellipticity at A222. CD spectra indicate an
alpha-helical structure, while the thermal melt shows negligible stepwise function for unfolding.
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in any quantity in the buffer also complicates data analysis as glycerol can participate in
the hydration sphere around the target protein and also sediment alone, both properties
affect determination of target protein sedimentation coefficients. In addition, glycerol
directly affects interference data, due to its viscosity. Both DTT and BME absorb in the
spectrum that is scanned (usually A280nm), and were therefore eliminated from buffers.
With these limitations the buffer used for initial AUC data collection was 20mM HEPES,
pH 7.5, 300mM NaCl. Samples of pooled and purified construct were concentrated to an
A280nm of approximately 1.0. Samples were dialyzed overnight in to AUC buffer to
provide a buffer blank for SV experiments. Overnight dialysis of the construct into the
original AUC buffer resulted in large amounts of aggregate and significantly reduced
protein concentration in solution. In addition, this aggregation left a buffer matching
problem, as salts would aggregate with protein and would be removed when aggregate was
spun down. The fringe residuals were significantly different (>0.2) between buffer alone
and buffer with protein that could not be attributed to protein. Even with the best-fit data
correlation of the program, the residuals were still consistently large down the length of
the cell. This data could not be used to conclusively determine oligomeric state.
In addition to sample difficulties, equipment failures also contributed to unusable
data runs. On numerous runs, the interference and absorbance data would be unusable due
to either malfunction of the collecting laser or buffer matching problems. Temperature
fluctuations were also noted. Numerous data collections were scrapped due to the fact that
the radiometer would record a temperature outside of the acceptable stable range of +/- 1

72
°C. Due to these issues, the optics system in the centrifuge was finally replaced, and the
temperature stability issue addressed.
Based on the fact that NAP 1-270 was more stable to 4°C, data collection for NAP
1-270 using the original buffer were completed at 4°C. However, due to a data collection
error, the computer stopped collecting data after 31 scans. The collection error stemmed
from the inability of data transfer between centrifuge and computer to occur on a fast
enough timescale to allow the machine to reset for the next scan. To overcome this error,
time per scan of cells was increased to 6 minutes. However, interference scans on 2 of the
3 cells are still consistently unusable.
Instead of pursuing NAP 1-270 that included a fragment, the NAP 255 construct
was used for further AUC analysis. To increase stability of constructs, glycerol but less salt
was added to the AUC buffer. To account for the hydration and sedimentation effect of
glycerol, parameters in the data analysis software were established by collaborator, Dr.
John Burgner. The final buffer composition was 20mM HEPES, pH 7.5, 150mM NaCl and
5% glycerol. Two runs of the exact same protein sample were collected at A280nm of 0.4
and 0.2. The data plot and fringe residuals are shown in Figure 20. The difference between
runs 1 and 2 was that in run 1 samples were allowed to equilibrate overnight at 4°C in the
cold room and then quickly transferred to the centrifuge versus in run 2 samples were
equilibrated at 4°C in the centrifuge. The second run was used to account for any
convection effects due to change in temperature between cold room, loading of cells and
placement in centrifuge in run 1.
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Figure 20. Analytical Ultracentrifugation Best-Fit Analysis of NAP255.

Figure 20. Analytical Ultracentrifugation Best-Fit Analysis of NAP255. Best-fit correlation of data from
NAP255 using SEDFIT. Top panel depicts the Data plot, middle panel depicts residuals and the bottom panel
is the C(s) distribution of the two concentrations of NAP 255 tested. Residuals are small, indicating a good fit
of the proposed model to the experimental data. The resulting correlated molecular weights and relevant
parameters used are listed in Table 3. The blue line is 18 µM and the red line is 9 µM.
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Best-fit analysis using SEDFIT were applied to the data plots from Figure 20 and gave
residuals that were small (<0.01). All scans were completed giving reliable results to base
analysis on for both runs. Table 3 reports parameters derived from the data. The
continuous sedimentation distribution plot shows that the major species’ sedimentation
coefficient (S) correlated to a molecular weight of 34.2 kDa (Expected monomer weight
of 32.2 kDa). Interestingly, the predicted S value of a dimeric NAP 1-255 was exceeded by
both samples for the second species. If the coiled-coil domains interact in anti-parallel
configuration, the KBD of each would extend past the self-associated coiled coil domain
region. This S value could also be attributed to the fact that SEDFIT uses the best frictional
coefficient to match the data, and the frictional coefficient for the dimer species, if it
interacts anti-parallel, would be larger. The failure to account for the difference in the
frictional ratio of the monomeric versus dimeric species could skew the predicted S value
larger, which in turn could give the correlated molecular weight of approximately a 2.5mer. Based on these analyses, no concentration dependence for the monomer-dimer
equilibrium, measured at 18.7 µM and 7.9 µM, was observed. Collection of data for SIKE
72 using the latest buffer was also collected. The data plot, residuals and C(s) for SIKE 72
are represented in Figure 21. Three distinct species are identifiable, corresponding to a
monomer, dimer and tetramer. Their C(s) distribution peaks have their MW listed in Table
3, along with relevant parameters from the best-fit analysis.
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Figure 21. Analytical Ultracentrifugation Best-fit Analysis of SIKE 72

Figure 21.Analytical Ultracentrifugation Best Fit Analysis of SIKE 72. Best-fit correlation of data from
SIKE 72 using SEDFIT. Data plot was omitted. Top panel depicts residuals and the bottom panel is the C(s)
distribution of SIKE 72 tested which was 16.5 µM. As you can see, residuals are small, indicating a good fit
of the proposed model to the experimental data. The resulting correlated molecular weights and relevant
parameters used are listed in Table 3.
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Table 3. Relevant Values from Best-Fit analysis of NAP 255 and SIKE 72.
Sample

f/f0

Overall
Peak 1
Peak 2

1.34

Overall
Peak 1
Peak 2
Peak 3

1.09

S-Value

Mass (kDa)

RMSD

NAP 255
0.0048
1.42
2.65

34.2
82.1

SIKE 72
0.0053
1.24
1.79
2.98

18.5
33.2
68.9
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3.2.5 Crystallization

Crystal screens using purified SIKE 72-207 at 6.98 mg/ml were attempted. A
factorial screen, Qiagen Classics Suite 96-well screen, was prepared and incubated at
18°C. Initial screens were visualized approximately 2 weeks after preparation. Wells were
scored 1-10 according to a scale developed by Hampton Research, 1 being clear with the
appearance of precipitate scoring a 3, crystalline material a 5, needle-like crystals a 7 and
individual crystals a 10. In the initial 96 conditions, approximately 30 conditions had a
score greater than 5, with none exceeding 7. Review of the conditions showed that SIKE
72 had a proclivity for polyethylene glycol (PEGs) conditions. A second 96-well screen
was prepared using the Qiagen PEGs Suite, and a protein concentration of 4.98 mg/ml.
Review after 2 weeks showed the a similar range in scoring. However, 4 months postloading review showed a crystal formation in the buffer 0.2M KF and 20% PEG3350.
Subsequent loading and x-Ray diffraction of this crystal showed both high resolution
diffraction consistent with salt crystals and low resolution powder diffraction consistent
with protein. Additional experiments need to be designed to determine whether or not
0.2M KF and 20% PEG 3350 or some minor alteration will crystallize SIKE 72.

3.3. Mammalian Cell Co-Immunoprecipitation
HEK293 Mammalian cells were transfected with pCMV-HA SIKE, harvested and
used to immunoprecipitate using Anti-HA agarose as outlined in methods. Two different
transfection reagents were used (Fugene®, Lipofectamine®), and samples were run on SDS-
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Figure 22. Immunoprecipitation of HA-SIKE FL
A.

B.

C.
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Figure 22. Immunoprecipitation of HA-SIKE FL. A. HEK 293 Mammalian cells were transfected with
either Fugene® (F) reagent or Lipofectamine® (L) reagent with pCMV-HA-SIKE FL DNA as per methods.
Resulting lysates were incubated with 20 µg of α-HA.11 Ab Affinity Agarose overnight. Samples were
washed, and loaded onto two SDS-PAGE gels, 20 µl of sample in each. One was visualized by coomassie
staining (Left), while another was used for western blot utilizing a Anti-HA antibody (Right). SIKE FL
transfection and pull down was successful using Lipofectamine®. B. HEK 293 cells were transfected with
pCMV-HA-SIKE FL as per Methods. After this point, cells were (un) stimulated with pI:pC for 24 hours.
Cell lysates were collected and immunoprecpitated with α-HA resin as per methods. Resulting samples were
separated by SDS-PAGE and transferred to nitrocellulose membrane for western blotting. Two separate
immunoblots utilizing the HA-IP sample were probed, with α-HA blot represented on the left, and an α-Ub
antibody represented on the right. There is no stepwise gain of 10 kDa to the original SIKE sample,
indicating it is not ubiquinylated. C. HEK 293 cells were transfected with pCMV-HA-SIKE FL per methods
and allowed to rest for 24 hours. After this point, cells were (un) stimulated with pI:pC for 24 hours. Cell
lysates were collected and immunoprecpitated with α-HA resin as per Methods. Resulting samples were
separated by SDS-PAGE and transferred to nitrocellulose membrane for western blotting. Two separate
immunoblots utilizing the HA-IP sample were run, with an α-HA blot represented on the left, and a αphospho-serine on the right. SIKE FL is phosphorylated prior to stimulation with pI:pC, and
dephosphorylated post-stimulation.
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PAGE and analyzed by western blot. Blots were screened with HA-antibody, and the
results from transfection are shown in Figure 22 A. Subsequent experiments utilizing
pulled down SIKE from mammalian cells were attempted. However, instead of blotting for
the HA construct, antibodies for a phospho-serine (SIKE has a predicted phosphorylation
site at S74), and for ubiquitin were used to delineate any post-translational modifications.
Transfected lysates of 293 cells stimulated with dsRNA for 24 hours and unstimulated
were collected and immunoprecipitated as per methods. Subsequent SDS-PAGE and
western blot using an anti-ubiquitin (B) and an anti-phosphoserine (C) antibody are shown
in Figure 22. SIKE is phosphorylated prior to stimulation, however upon stimulation and
activation of the pathway, SIKE is dephosphorylated.

The question that remains is

whether this phosphorylation is required for binding and inhibition of SIKE to the kinase
activity. While SIKE from 293 cells is not ubiquinylated, introduction and blotting of this
same construct into immune cells is necessary, as the machinery that might be required for
ubiquinylation of SIKE may be absent in 293 cells.
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Chapter 4. Discussion

Protein-protein interaction networks form the backbone of signaling responses.
While the field has progressed at a rapid rate in terms of understanding the role of various
players to mediate activation/regulation, the interferon pathway of TLR3 present some
novel twists. The incorporation of three scaffolds represents a unique element in this
pathway [30]. While one scaffold has been shown to be both phosphorylated by TBK-1 and
K-63 ubiquitinylated, the functional consequences of these modifications on kinase activity
are unknown [27]. In addition, two alternative scaffolds have been identified, however,
with the exception of identifying complexing partners, little insight into their function has
been reported [28,30]. SIKE interactions and potential complexing partners have been
reported [31]. However, the mechanism by which SIKE inhibits kinase activity remains
unknown. SIKE may act through sequestering the kinases or preventing homo- or heterointeractions. The role of post-translation modification in SIKE function is completely
unexplored. With all these proteins, direct interactions have not been identified, though coimmunoprecipitation experiments imply association between the three functionally
different types of proteins involved in the kinase complex of this pathway [30,31].
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Establishing direct interactions is essential to identifying motifs required for activation or
regulation of this system.
Understanding normal activation/regulation of this system may reveal how viral
subversion or dysregulation found in disease states evolved. The interferon response
partially mediated by the TLR3 pathway can be utilized to selectively target cell
populations for death through apoptosis [36]. Ebola and Hepatitis C virus, along with a
multitude of other infectious agents, have evolved multiple mechanisms to evade this
specific signaling response [3,4]. Inhibiting the interferon pathway, by sequestering the
activating ligand, dsRNA, or directly inhibiting signal transduction, has allowed viruses to
increase infectivity and replication in a host [4]. Therefore, in order to fully understand
viral mechanisms of inhibition and to develop a means to prevent or reverse viral
subversion, endogenous activation and control of this pathway must be defined.
The potential therapeutic applications of pathway activation have already been
documented. Administration of polyinosinic:polycytidylic acid (pI:pC), a synthetic mimic
of viral dsRNA, increased expression of type I interferon but caused side effects including
shock, renal failure, coagulopathies, and hypersensitivity reactions [37]. Intravenous
interferon-β, the downstream effector, suffers from a limited half-life [38,39]. Alternatively,
interferon-β delivered via replicative-incompetent adenovirus has been shown to illicit a
tumor-specific humoral immune response, however down regulation of targeted MCH
class expression allowed tumor escape mutants to develop reducing the efficacy of this
treatment in clinical trials [39]. While preliminary cell-based research has shown that both
pI:pC and IFN-β can have positive effects with regard to cancer cell apoptosis and
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initiation of a selective immune response, implementation of this effect in a clinical setting
has met with limited success. With these limitations, one must begin to question what
alternative methods need to be approached to activate this pathway. One approach may be
selective removal of inhibition. Alternatively, IKK-ε has been show to be hyperactive in
breast cancer [39] and subsequent knockdown has been shown to induce apoptosis
indicating that reinstituting control of this kinase in targeted situations could be an
effective avenue of treatment.
While alternative inhibitors can silence portions of the TLR-3 response, SIKE
alone stands as the selective inhibitor of TBK-1 and IKK-ε activity [24,31,33,35]. The
removal of this inhibition allows for phosphorylation of IRF3, required for IFN-β
transcription. To realize the therapeutic potential of IFN-β, a process to selectively
decrease SIKE production or increase SIKE degradation of SIKE or alter its inhibitory
properties with respect to activity of TBK-1 and IKK-ε may be beneficial. However,
before a system can be altered, its endogenous mechanism to inhibit kinetic activity, and
how this inhibition is removed must be defined. My initial studies indicate that a
phosphorylation event might be a critical component of this control. With respect to the
scaffolds, further study is needed to understand their effect on kinase activity and if
scaffold can protect kinase from SIKE inhibition.
The main conclusions from the research presented in this thesis are as follows: First
and foremost, SIKE FL and SIKE 72 are mostly insoluble both alone and when coexpressed with either of the kinases. This indicates that SIKE either does not bind directly
to TBK1 or IKKε, or does not do so with high affinity, or binding may require post-
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translational modification(s), The serine phosphorylation of SIKE observed in vivo prior to
dsRNA stimulation but absent following dsRNA stimulation may serve as a switch for
SIKE:kinase complex. Experiments in vitro using SIKE constructs to mimic a
phosphorylation event could then be used to elucidate if this phosphorylation event is
necessary for complex formation. Future in vivo experiments will need to define the
phosphorylation site, if, in fact, the phosphorylation site coincides with the predicted serine
74 phosphorylation site [40]. Additionally, NAP 270 and NAP 255 are insoluble in
bacterial expression. NAP 255 binds to TBK1 in vitro as assessed by co-precipitation
experiments. Based on this analysis, further studies again utilizing HEK 293 cell
transfections of full-length NAP1 and TBK1 have been planned to help delineate the
modifications, if any, which might alter the affinity for binding of NAP1 to TBK1.
From AUC experiments, NAP 255 forms mostly a monomer. Our analysis of this
data may be biased by the non-ideal buffer conditions required for sample preparation,
including the addition of glycerol. Further study by dynamic light scattering that could be
coupled to the AUC data may allow a consistent interpretation of the data. As NAP1-200
forms a stable dimer, the transition to a monomer form by the addition of 55 amino acids
in NAP1-255 is surprising. By coupling two methods, a better approximation of the
oligomeric state may be obtained. As only a single SIKE 72 concentration was analyzed by
AUC, more data collected at several concentrations will be necessary to deduce any insight
on concentration dependence of oligomeric state. However, initial studies show that SIKE
72 has higher order self-associations predominantly as a dimer. Small amount of tetramer
and monomer species are present.
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Previous studies showing a complex of approximately 670 kDa that incorporates
scaffolds, kinases and SIKE begs the question of stoichiometry within the complex [31].
Interestingly, a partial TRAF-3 x-ray structure revealed a trimer subunit arrangement [41]
would be located upstream of the kinase complex. If working from a trimeric scaffold,
three NAP1 dimers could form a platform for six kinase docking events giving a complex
of 875 kDa. This higher order complex has been observed for the activation of caspase in
the apoptosome [42] the inflammasome [43] and, more recently, with an innate immune
signaling complex involving MyD88, the Myddosome [44]. Although precedence exists for
large, ordered complexes, we must first better define our potential interaction partners.
Experimentation to determine the post-translational modifications of NAP1 are underway,
which could lead to significant insight into potential necessity of modifications for
complex formation. Competition between scaffold and inhibitor for a single kinase-binding
site may determine the inclusion/exclusion from a signaling complex. The most interesting
result from this current work was that SIKE was phosphorylated prior to stimulation with
pI:pC and dephosphorylated following stimulation. As SIKE is constitutively bound to
TBK1 but released upon pathway stimulation, the addition of a phosphate group would
suggest this phosphorylation event might be critical to binding. The question remains
whether this phosphorylation directly correlate to kinetic inhibition of the kinase. Two key
experiments would highlight the role of this post-translational modification: 1) engineer a
construct of SIKE that incorporates a phosphomimetic (Glu or Asp) at S74 to assess
function and 2) identify the kinase/phosphatase responsible for addition/removal of this
post-translation modification. These experiments could lead to either new targets for the
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intrinsic control of the pathway or a reveal a novel link between signaling cascades to
illicit regulation of the innate immune response.

Literature Cited

[1-45]
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.

Janeway, C.A.T., P. Walport, M. Shlomchik, M.J., Immuno-Biology; the immune
system in health and disease. 6th ed. 2005, New York: Garland Science. 823.
Paul, W.E., Fundamental Immunology. 5th Edition ed. 2003, Philadelphia:
Lippincott, Williams & Wilkins. 1687.
Jin, H., et al., The VP35 protein of Ebola virus impairs dendritic cell maturation
induced by virus and lipopolysaccharide. J Gen Virol. 91(Pt 2): p. 352-61.
Bowie, A.G. and L. Unterholzner, Viral evasion and subversion of patternrecognition receptor signalling. Nat Rev Immunol, 2008. 8(12): p. 911-22.
Kandyil, R.M. and C.M. Davis, Shellfish allergy in children. Pediatr Allergy
Immunol, 2009. 20(5): p. 408-14; quiz 414.
Mason, J.M. and K.M. Arndt, Coiled coil domains: stability, specificity, and
biological implications. Chembiochem, 2004. 5(2): p. 170-6.
Metz-Boutigue, M.H., et al., Antimicrobial Peptides Present in Mammalian Skin
and Gut are Multifunctional Defence Molecules. Curr Pharm Des, 2009.
Lemaitre, B., et al., The dorsoventral regulatory gene cassette spatzle/Toll/cactus
controls the potent antifungal response in Drosophila adults. Cell, 1996. 86(6): p.
973-83.
Deva, R., et al., Candida albicans induces selectively transcriptional activation of
cyclooxygenase-2 in HeLa cells: pivotal roles of Toll-like receptors, p38 mitogenactivated protein kinase, and NF-kappa B. J Immunol, 2003. 171(6): p. 3047-55.
Medzhitov, R., P. Preston-Hurlburt, and C.A. Janeway, Jr., A human homologue of
the Drosophila Toll protein signals activation of adaptive immunity. Nature, 1997.
388(6640): p. 394-7.
Poltorak, A., et al., Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice:
mutations in Tlr4 gene. Science, 1998. 282(5396): p. 2085-8.
Visintin, A., et al., Secreted MD-2 is a large polymeric protein that efficiently
confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci U
S A, 2001. 98(21): p. 12156-61.
Matsumoto, M., et al., Subcellular localization of Toll-like receptor 3 in human
dendritic cells. J Immunol, 2003. 171(6): p. 3154-62.
Pisegna, S., et al., p38 MAPK activation controls the TLR3-mediated up-regulation
of cytotoxicity and cytokine production in human NK cells. Blood, 2004. 104(13):
p. 4157-64.
87

88
15.
16.
17.
18.

19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.

Schmidt, K.N., et al., APC-independent activation of NK cells by the Toll-like
receptor 3 agonist double-stranded RNA. J Immunol, 2004. 172(1): p. 138-43.
Sivori, S., et al., CpG and double-stranded RNA trigger human NK cells by Tolllike receptors: induction of cytokine release and cytotoxicity against tumors and
dendritic cells. Proc Natl Acad Sci U S A, 2004. 101(27): p. 10116-21.
Kulka, M., et al., Activation of mast cells by double-stranded RNA: evidence for
activation through Toll-like receptor 3. J Allergy Clin Immunol, 2004. 114(1): p.
174-82.
Matsushima, H., et al., TLR3-, TLR7-, and TLR9-mediated production of
proinflammatory cytokines and chemokines from murine connective tissue type
skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol,
2004. 173(1): p. 531-41.
Matsumoto, M., et al., Establishment of a monoclonal antibody against human
Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem
Biophys Res Commun, 2002. 293(5): p. 1364-9.
Kaiser, W.J., J.L. Kaufman, and M.K. Offermann, IFN-alpha sensitizes human
umbilical vein endothelial cells to apoptosis induced by double-stranded RNA. J
Immunol, 2004. 172(3): p. 1699-710.
Akira, S., TLR signaling. Curr Top Microbiol Immunol, 2006. 311: p. 1-16.
Sen, G.C. and S.N. Sarkar, Transcriptional signaling by double-stranded RNA: role
of TLR3. Cytokine Growth Factor Rev, 2005. 16(1): p. 1-14.
Hasan, U., et al., Human TLR10 is a functional receptor, expressed by B cells and
plasmacytoid dendritic cells, which activates gene transcription through MyD88. J
Immunol, 2005. 174(5): p. 2942-50.
Vercammen, E., J. Staal, and R. Beyaert, Sensing of viral infection and activation
of innate immunity by toll-like receptor 3. Clin Microbiol Rev, 2008. 21(1): p. 1325.
Santoro, M.G., et al., The relationship between the antiviral action of interferon
and prostaglandins in virus-infected murine cells. Biochem Biophys Res Commun,
1983. 116(2): p. 442-8.
Shaw, A.S. and E.L. Filbert, Scaffold proteins and immune-cell signalling. Nat Rev
Immunol, 2009. 9(1): p. 47-56.
Gatot, J.S., et al., Lipopolysaccharide-mediated interferon regulatory factor
activation involves TBK1-IKKepsilon-dependent Lys(63)-linked polyubiquitination
and phosphorylation of TANK/I-TRAF. J Biol Chem, 2007. 282(43): p. 31131-46.
Sasai, M., M. Matsumoto, and T. Seya, The kinase complex responsible for IRF-3mediated IFN-beta production in myeloid dendritic cells (mDC). J Biochem, 2006.
139(2): p. 171-5.
Sasai, M., et al., Cutting Edge: NF-kappaB-activating kinase-associated protein 1
participates in TLR3/Toll-IL-1 homology domain-containing adapter molecule-1mediated IFN regulatory factor 3 activation. J Immunol, 2005. 174(1): p. 27-30.

89
30.
31.
32.
33.
34.

35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.

Ryzhakov, G. and F. Randow, SINTBAD, a novel component of innate antiviral
immunity, shares a TBK1-binding domain with NAP1 and TANK. EMBO J, 2007.
26(13): p. 3180-90.
Huang, J., et al., SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and
virus-triggered IRF-3 activation pathways. EMBO J, 2005. 24(23): p. 4018-28.
Saitoh, T., et al., A20 is a negative regulator of IFN regulatory factor 3 signaling. J
Immunol, 2005. 174(3): p. 1507-12.
You, M., D.H. Yu, and G.S. Feng, Shp-2 tyrosine phosphatase functions as a
negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol,
1999. 19(3): p. 2416-24.
Schroder, K., et al., Differential effects of CpG DNA on IFN-beta induction and
STAT1 activation in murine macrophages versus dendritic cells: alternatively
activated STAT1 negatively regulates TLR signaling in macrophages. J Immunol,
2007. 179(6): p. 3495-503.
An, H., et al., SHP-2 phosphatase negatively regulates the TRIF adaptor proteindependent type I interferon and proinflammatory cytokine production. Immunity,
2006. 25(6): p. 919-28.
Morrison, B.H., et al., Apo2L/TRAIL induction and nuclear translocation of
inositol hexakisphosphate kinase 2 during IFN-beta-induced apoptosis in ovarian
carcinoma. Biochem J, 2005. 385(Pt 2): p. 595-603.
Robinson, J.H., et al., Transition probability and the hormonal and densitydependent regulation of cell proliferation. Nature, 1976. 262(5566): p. 298-300.
Arnaud, P., [The interferons: pharmacology, mechanism of action, tolerance and
side effects]. Rev Med Interne, 2002. 23 Suppl 4: p. 449s-458s.
Markman, M., et al., Phase 2 trial of interferon-beta as second-line treatment of
ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum.
Oncology, 2004. 66(5): p. 343-6.
Boehm, J.S., et al., Integrative genomic approaches identify IKBKE as a breast
cancer oncogene. Cell, 2007. 129(6): p. 1065-79.
Matsuoka, S., et al., ATM and ATR substrate analysis reveals extensive protein
networks responsive to DNA damage. Science, 2007. 316(5828): p. 1160-6.
Ni, C.Z., et al., Molecular basis for CD40 signaling mediated by TRAF3. Proc Natl
Acad Sci U S A, 2000. 97(19): p. 10395-9.
Li, P., et al., Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9
complex initiates an apoptotic protease cascade. Cell, 1997. 91(4): p. 479-89.
Martinon, F. and J. Tschopp, Inflammatory caspases: linking an intracellular
innate immune system to autoinflammatory diseases. Cell, 2004. 117(5): p. 561-74.
Motshwene, P.G., et al., An oligomeric signaling platform formed by the Toll-like
receptor signal transducers MyD88 and IRAK-4. J Biol Chem, 2009. 284(37): p.
25404-11.

90
46.

Dam, J., et al., Sedimentation velocity analysis of heterogeneous protein-protein
interactions: Lamm equation modeling and sedimentation coefficient distributions
c(s). Biophys J, 2005. 89(1): p. 619-34.

91

VITA

Jonathan L. Forbes was born in Syracuse, New York, U.S.A. in 1984. Upon
graduating from Jamesville Dewitt High School, he attended the State University of New
York at Buffalo, graduating with a Bachelor of Arts in Biological Sciences in 2008. His
current publications include “Identification of an antiparallel coiled-coil/loop domain
required for ligand binding by the Borrelia hermsii FhbA protein: additional evidence for
the role of FhbA in the host-pathogen interaction” in the journal, Infection and Immunity
(2008). He received his Master of Science degree in Biochemistry and Molecular Biology
from Virginia Commonwealth University in May 2010. He plans to pursue a career in the
medicines and medical research.

